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ABSTRACT 
Mesenchymal stem cells are multipotent cells that can differentiate into 
many cell types. However, the molecular mechanism controlling this process 
remains unclear. We utilized rat dental follicle stem cells (rDFSCs) and human 
adipose derived stem cells (hASCs) to study the mechanisms controlling 
osteogenesis and adipogenesis. Elevations in the intracellular Ca2+ concentration 
are a phenomenon commonly observed during stem cell differentiation but cease 
after the process is complete. The Transient Receptor Potential Melastatin 4 
(TRPM4) is an ion channel that controls Ca2+ signals in excitable and non-excitable 
cells. However, there are no studies on TRPM4 in stem cells. In another study, we 
investigate the mechanism by which arginine vasopressin (AVP), a neuropeptide 
hormone secreted mostly from the posterior pituitary gland increased Ca2+ signals 
and inhibited adipogenesis in hASCs.  
The overall goal of our studies is to investigate the effect of TRPM4 and 
AVP on stem cell differentiation and Ca2+ signaling. First, we 
identified TRPM4 gene expression and its characteristics such as Ca2+-activated, 
voltage dependent and monovalent conducting properties in rDFSCs. Molecular 
suppression of TRPM4 transformed the normal agonist-induced first and secondary 
phases of Ca2+ signals into a gradual and sustained increase which enhanced 
osteogenesis but inhibited adipogenesis in rDFSCs. Next, we examined TRPM4’s 
impact on Ca2+ signals and adipogenesis in hASCs, which is a more suitable stem 
cell type for adipogenic studies. Suppression of the TRPM4 diminished the 
histamine-induced Ca2+ signals mainly via H1 receptors. The increases in 
xv 
 
intracellular Ca2+ were due to influx via voltage-dependent Ca2+ channels of the L-
type (Cav1.2) and release from the endoplasmic reticulum (ER). Lastly, we 
determined the role of AVP on adipogenesis in hASCs. These cells were responsive 
to AVP stimulation by increasing intracellular Ca2+ via V1a receptors, Gq-proteins 
and the PLC-IP3 pathway. Both Ca
2+ release from the ER and influx from the 
extracellular space contribute to the Ca2+ signals. AVP supplementation to the 
differentiation media decreased the number of adipocytes during adipogenesis. The 
effect of AVP on adipocyte formation was reversed by the V1a receptor blocker 
V2255. In conclusion, TRPM4 and AVP control Ca2+ signals which affect stem cell 
differentiation. 
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CHAPTER 1: STEM CELLS AND Ca2+ SIGNALING  
  
1.1 STEM CELLS 
Stem cells are cells that have capacity for self-renewal, clonogenic entity 
and potency [1]. Stem cell research is focused on tissue/adult stem cells, embryonic 
stem cells and induced pluripotent stem cells. Also, cancer stem cells are being used 
to develop diagnostic tests and effective anti-tumor therapy [1]. 
1.1.1 Embryonic stem cells  
Embryonic stem cells (ESCs) are pluripotent cells derived from the inner 
cell mass of the blastocyst that can differentiate into all cell types except placenta 
[2]. They are promising for tissue engineering because of their proliferation 
capability and sustained potency. However, there are ethical issues preventing their 
use. In addition, they can cause tumors and immune rejection after transplanted into 
patients [3]. 
1.1.2 Induced pluripotent stem cells  
Induced pluripotent stem cells (iPSCs) are somatic cells that are 
reprogrammed to become pluripotent like ESCs [4]. Yamanaka’s group utilized 
retroviral expression of 4 transcription factors (Oct4, Sox2, Klf4 and c-Myc) in 
mouse fibroblast to generate embryonic stem cell-like cells [4]. Next, Yu’s group 
utilized Lin-28 instead of c-Myc to induce iPSCs from human somatic cells [5]. 
Currently, there are various approaches to induce iPSCs such as RNA 
reprogramming (miRNAs, RNA virion, RNA replicon), protein, polycistron, and 
non-replicating plasmids (Figure 1.1) [6]. iPSCs have advantages because of the 
absence of ethical issues. Furthermore, they can differentiate into three germ layers, 
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proliferate continuously in vitro, and can be used for future disease treatment. These 
cells open new opportunities for regenerative medicine and stem cell modeling of 
human disease [7]. However, their disadvantages are low reprogramming 
efficiency, potential for genetic and epigenetic abnormalities, tumorigenicity, and 
immunogenicity of transplant cells [6-8].  
 
Figure 1.1 Reprogramming pluripotent stem cells (Modified from [9] and        
http://www.rndsystems.com/Cytokine_cb09i2_induced_pluripotent_stem_cells.as
px.) 
 
1.1.3 Cancer stem cells  
 
Cancer stem cells (CSCs) are derived from damaged or mutated stem 
cells/progenitor cells that have self-renewal, differentiation and tumor generating 
properties [1, 10]. Despite their limited numbers, CSCs are a major cause of tumors. 
They share some similar signaling pathways with normal stem cells like Bmi-1 and 
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Wnt signaling [10]. They are hereditary, unstable, and highly resistant to 
chemotherapy and radiotherapy. CSCs are thought to be responsive for tumor 
regrowth after conventional radiation treatment.  
1.1.4 Adult stem cells  
Adult stem cells (AdSCs) are cells derived from postembryonic stage tissue 
with self-renewal capability and multipotency [1]. They include hematopoietic, 
neural, epithelial, skin, and mesenchymal stem cells (MSCs). This last type is 
present in many tissues such as bone marrow, dental follicle and fat. DFSCs are 
isolated from medical waste, unerupted third molars and have advantages such as 
ease to collect with high efficiency, low morbidity, and good for bone regeneration 
in osteoporosis [11, 12]. hASCs from adipose tissue have minimal loss of 
differentiation potential after cryopreservation which make this kind of stem cell a 
potential source for tissue regeneration [13, 14]. As AdSCs are taken from patients, 
immune rejection and teratoma will not occur when transplanted back to the same 
patients. For example, bone marrow-derived stem cells (BMSCs) are used to treat 
leukemia, lymphoma, and several inherited blood disorders [15].  
1.1.4.1 Dental follicle stem cells  
The dental follicle is a loose connective tissue around the developing tooth 
and is composed of different cell populations derived from the cranial neural crest. 
Bovine dental follicle contains precursor cells that can differentiate into cementum 
matrix after being transplanted into mice [16, 17]. Dental follicle precursors/stem 
cells express putative stem cell markers such as nestin, Notch-1, STRO-1, Oct4, 
and Nanog as well as mesenchymal stem cell-related surface antigens like CD13, 
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CD29, CD44, CD73, and CD105 [18-20]. Hypoxia increases the growth and 
differentiation compared to normoxia [21]. DFSCs can proliferate, form colonies 
and be harvested at a large volume [20, 22, 23]. In addition, they differentiate into 
adipocytes better than dental pulp stem cells (DPSCs) but have lower potential to 
form chondrocytes, and osteoblasts [24]. The osteogenic potential of hDFSCs is 
higher than hASCs while the opposite is observed during adipogenesis [25]. After 
cryopreservation, many characteristics of DFSCs such as expression of stem cell 
markers, proliferation, differentiation, apoptosis and transcription-related genes are 
unchanged [26]. DFSCs lose their osteogenic properties about passage 11 [27]. 
Under heat-stress culture condition, there is increased cell proliferation, 
osteogenesis and expression of marker genes such as BMP2, BMP6, Col3a1, Flt1, 
Runx2 and SPP1 [28]. Under serum-free conditions, DFSCs form spheroid clusters 
through focal adhesion kinase signaling [29]. Cementoblast formation from DFSCs 
involves BMP2/7, MAPK and Smad1 pathway when stimulated by enamel matrix 
derivatives in vitro [30]. BMP-9 promotes osteogenesis by activating p38MAPK 
pathway and inhibiting ERK1/2 activity in rDFSCs [31]. Notch1 signaling is 
activated by DLX3 during proliferation and self-renewal in hDFSCs and impairs 
osteogenesis by downregulating BMP2/DLX3 [32, 33]. BMP4 and BMP6 are 
involved in osteogenic differentiation of DFSCs since they are upregulated after 
three days in osteogenic induction media [34]. High levels of BMP6 are required 
to maintain their osteogenic capability because knockdown reduces osteogenesis 
[27]. Transcription factors such as TP53 improves DFSC proliferation while SP1 
stimulates osteogenesis [35]. Early growth response gene 1 increases osteogenesis 
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in hDFSCs by facilitating BMP2 and DLX3 expression [36]. Purinergic 
receptor P2X6, P2Y4 and P2Y14 receptors are also involved in osteogenic and 
adipogenic induction of hDFSCs and hASCs [37].  
1.1.4.2 Human adipose-derived stem cells  
The origin of hASCs is from the mesoderm layer of the embryo [38]. They 
are multipotent cells that can differentiate into adipocytes, chondrocytes, 
osteoblasts, hepatocytes, myocytes, and pancreatic cells [13]. They have 
fibroblastic morphology and colony-forming unit ability; they share similar surface 
antigens with other MSCs such as CD44+, CD73+, CD90+, CD105+, CD45-, and 
CD31- [39]. The immunogenicity of hASCs after passage 2 fails to show T 
lymphocyte reaction during in vitro expansion [40]. In addition, hASCs can cause 
dendritic cell tolerance when being co-cultured by inhibiting CD4+ T cell activation 
[41]. They have normal karyotype, reduced telomerase levels and cease 
proliferation at passage 30 [42]. hASCs from different donors vary in adipogenic 
capability [43]. Intracellular Ca2+ oscillations in undifferentiated hASCs may be 
involved in stem cell maintenance and are dependent on Ca2+ release and influx 
[44]. ERK suppression inhibits osteogenesis but induces adipogenesis [45, 46]. 
Endogenous Wnt signaling inhibits osteogenesis but has no effect on adipogenesis 
while Notch signaling inhibits adipogenesis [47, 48]. The Hedgehog signaling 
pathway is involved in adipocyte maturation by reducing C/EBPα and PPARγ 
expression and insulin sensitivity [49]. Nell-1 signaling crosstalks with the 
Hedgehog pathway to inhibit adipogenesis [50]. Epidermal and fibroblast growth 
factors facilitate proliferation and increase adipogenesis and insulin sensitivity [51]. 
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miRNAs, such as miR-17-5p, miR-106a and miR-22 also regulate osteogenesis and 
adipogenesis [52, 53]. Hypoxia can invoke adipogenesis by stimulating the 
PI3K/Akt/mTOR pathway [54]. Autologous platelet-rich plasma and insulin 
treatment stimulate adipogenic differentiation via Akt [55]. Therefore, many 
signaling pathways control adipogenesis and osteogenesis in AdSCs but the role of 
Ca2+ signaling on differentiation remain largely unknown.  
1.2 CALCIUM SIGNALING IN STEM CELLS 
Intracellular Ca2+ signaling controls many processes such as fertilization, 
proliferation, development, differentiation, contraction, and secretion [56]. Stem 
cells have ion channels on their plasma membrane that regulate Ca2+ movement 
into cells. Below is an overview of different Ca2+ channels and signaling pathways. 
1.2.1 Voltage dependent Ca2+ channels  
Voltage dependent Ca2+ channels (VDCCs) are mostly expressed in 
excitable cells like neuron, skeletal muscle, and heart cells [57]. Due to the 
depolarization, VDCCs open to stimulate Ca2+ influx into the cells, leading to 
various cellular responses such as hormone secretion, neurotransmitter release, and 
muscle contraction [57]. However, there are reports of VDCCs in non-excitable 
cells such as microglial cells and T lymphocytes [58, 59]. VDCCs may play a role 
in histamine release from human basophils [60]. In stem cells, hBMSCs express 
functional L-type VDCCs of the Cav1.2 type [61, 62]. hASCs also have L-type 
VDCCs (Cav1.2) and T-type VDCCs (Cav3.2) [63]. In rDPSCs, the Cav1.2 is 
needed for neural differentiation as knockdown inhibits differentiation [64].  
 
7 
 
1.2.2 Store-operated Ca2+ channels  
Store-operated Ca2+ channels (SOCs) also known as Ca2+ release-activated 
Ca2+ channels (CRAC) are activated by the phospholipase C (PLC) pathway which 
catalyzes phosphatidylinositol-4,5-biphosphate (PIP2) to inositol-1,4,5-
triphosphate (IP3) that binds to the ER to promote  Ca
2+ release into the cytoplasm 
[65]. When the ER is exhausted of Ca2+, stromal interaction molecule (STIM), a 
Ca2+ ER sensor, translocates to SOCs to promote Ca2+ influx [66]. This channel is 
the main Ca2+ entry pathway in non-excitable cells [67]. It is highly selective for 
Ca2+ ions and is only permeable to monovalent cations in divalent free cation 
extracellular solution [68, 69]. Mutation of two conserved negatively charged 
glutamate residues decreases the Ca2+ entry via SOCs in T lymphocytes [70]. The 
Orai1, Orai2, Orai3 are the main components of SOCs while the first is the pore of 
the channel [71-73]. Orai1 is a membrane protein with four transmembrane 
segments with intracellular C and N terminus [70, 71]. Orai1 or Orai2/Orai3 
overexpression with STIM1 amplify CRAC currents; Orai1, not Orai2 or Orai3, is 
inhibited by intracellular Ca2+ [73, 74]. Orai1 and STIM1 are important for AVP-
induced Ca2+ oscillations and entry in rat hepatocytes [75]. The CRAC channel is 
also regulated by pH because acidification diminishes while alkalization facilitates 
its activity [76]. 
1.2.3 The phospholipase C - Inositol triphosphate pathway  
Phospholipase C was first reported from amylase secretion in the pancreas 
treated with acetylcholine and carbamylcholine [77]. Later, PLC was identified as 
the enzyme catalyzing PIP2 to IP3 and diacylglycerol (DAG) [78]. There are 13 
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PLC family members that are subdivided into 6 classes (β, γ, δ, ζ, ε, and η) [79]. 
PLCβ, PLCδ and PLCη are linked to Gq-couple receptors; however, PLCγ and 
PLCζ, are connected to tyrosine-kinase receptors while PLCε is attached to both 
receptors [79].  
Inositol-1,4,5-triphosphate’s function was determined when pancreatic 
acinar cells released ER Ca2+ during carbachol stimulation [80, 81]. There are 3 
types of IP3R: IP3R1, IP3R2 and IP3R3 [82]. IP3R is a major contributor to Ca
2+ 
release from the ER in undifferentiated hBMSCs [62]. IP3-induced Ca
2+ release is 
crucial for spontaneous Ca
2+ oscillations in stem cells [83-85]. Human 
preadipocytes have all three IP3Rs that are involved in intracellular Ca
2+
 oscillations 
[86].   
1.3 EFFECT OF TRPM4 ON Ca2+ SIGNALING 
1.3.1 Overview of TRP channels  
Transient receptor potential (TRP) ion channels were first reported in 
Drosophila melanogaster [87]. They are divided into 7 subfamilies: The canonical 
(TRPC), vallinoid (TRPV), melastatin (TRPM), ankyrin (TRPA), mucolipin 
(TRPML), polycystin (TRPP), and Drosophila no mechano-potential C (TRPN). 
All channels have six transmembrane segments with the pore region between the 
5th and 6th segments and C- and N-terminal domains in the intracellular space 
(Figure 1.2).  
TRPC has 7 members (TRPC1-7) and is the most characterized subfamily. 
TRPC is activated by DAG from receptor-induced PLC activation, or stimulation 
of translocation to the plasma membrane, or by depletion of ER Ca2+ [88, 89]. It is 
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involved in different cellular processes such as keratinocyte Ca2+ homeostasis, 
myoblast differentiation and cardiac hypertrophy [90-92].  
TRPV is composed of 6 members (TRPV1-6). It is activated by vanilloid, 
vanilloid-like compounds and heat [93]. The most well-known member is TRPV1 
(also known as capsaicin-activated/capsaicin receptor). TRPV1 activation prevents 
adipogenesis and obesity by increasing energy expenditure [94, 95]. TRPV4 
inhibits adipogenesis in TRPV4 knockout mice or wild-type mice treated with a 
TRPV4 antagonist by improving insulin sensitivity and reducing obesity and 
adipose inflammation [96].  
 
Figure 1.2 TRP family of ion channels (Reprinted with permission from Elsevier 
Ltd. Authors: Piper Nelson, Andreas Beck and Henrique Cheng. Vet. J. 2011; 
187:153-164.) 
 
TRPA includes three Drosophila, two Caenorhabditis elegans and one 
mammalian member known as TRPA1. TRPA1 is expressed in chemosensory C-
fibers and activated by polygodial, acrolein and crotonaldehyde. They are 
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involved in inflammatory pain signaling during asthma and chronic obstructive 
pulmonary disease [87, 97]. TRPA1 knockout or wild-type mice treated with 
TRPA1 antagonists show reduced pain and inflammation [98].  
TRPN is found in Caenorhabditis elegans, Drosophila and zebrafish. It is 
the primary transduction channel in Drosophila mechanosensory cilia in both 
external and chordotonal sensory neurons [99]. TRPML is composed of 3 members 
(TRPML1-3). They are expressed in intracellular vesicles of the endolysosome 
system [100, 101]. TRPP is a mechanosensor channel, existing in kidneys and 
ovaries where it responds to fluid movement in kidney and follicle maturation and 
differentiation in ovaries [87].  
The TRPM subfamily includes 8 members (TRPM1-8). TRPM1 was named 
after it was found as a tumor suppressor gene in melanoma cells [102]. Mutation of 
TRPM1 is observed in patients with autosomal-recessive complete congenital 
stationary night blindness [103].  TRPM2 has a Nudix enzyme domain in the C-
terminal that is activated by heat, β-NAD+, ADP-ribose and hydrogen peroxide, but 
is suppressed by intracellular ATP [104-107]. It increases Ca2+ oscillations and cell 
proliferation in hBMSCs but has no effect on osteogenesis and adipogenesis [108]. 
TRPM3 exists in the brain and kidneys where its activity is increased by 
sphingosine derivatives and hypotonic solution and is involved in Ca2+ homeostasis 
[109, 110]. Among all TRPM channels, only TRPM4 and TRPM5 channels are 
Ca2+ impermeable. In spite of conducting Na+, they have a profound effect on 
intracellular Ca2+ signals because the depolarization resulting from channel opening 
controls the activation of Ca2+ channels in the plasma membrane. TRPM5, which 
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shares 50% sequence homology with TRPM4, is found in the intestines, taste 
receptors, brain, and pancreatic β cells [111, 112]. TRPM2 and TRPM5 control 
Ca2+ signals and insulin secretion from pancreatic β cells [113-116]. TRPM6 and 
TRPM7 are also ‘chanzymes’ with alpha-kinase domain in the C-terminal region 
and facilitates Ca2+ and Mg2+ influx. TRPM6 is expressed in intestinal epithelia and 
kidney tubule cells and is important for Mg2+ homeostasis [117]. Mutation of 
TRPM6 induces hypomagnesemia with secondary hypocalcemia and patients with 
this defect have abnormal renal Mg2+ excretion [118]. TRPM6 knockout mice have 
lower survival rates, neural tube defects, and infertility [119]. TRPM7 is essential 
for MSC and ESC survival, proliferation as well as osteoblast differentiation and 
osteogenesis [120-122]. It is important for proliferation and adipogenesis of 
preadipocytes, as channel suppression inhibits these processes [123]. TRPM8 is 
predominantly expressed in dorsal root ganglia and neurons from trigeminal 
ganglia and is activated by cold and cooling agents such as menthol and icilin [124, 
125]. Brown adipose tissue (BAT) express TRPM8, and when activated, it will 
enhance uncoupling protein 1 production for thermogenesis and prevention of 
obesity [126].  
1.3.2 TRPM4 
TRPM4 is a Ca2+-activated non selective cation (CAN) channel [127]. They 
form tetramers to make a functional unit. Its selectivity filter is linked to six amino 
acids between the 5th and 6th transmembrane helices. Mutations of Glu981, Asp982 
and Asp984 to Ala shifts the voltage dependency to a more positive potential and 
replacement of Gln977 with Glu enables Ca2+ permeability [128]. Its structure 
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includes ATP, calmodulin and protein kinase C (PKC) binding sites [129]. Two 
divalent cation binding sites and negatively charged amino acids in the C-terminus 
help preserve the normal Ca2+ sensitivity [130]. TRPM4 is ubiquitously expressed 
throughout the body [102, 127, 131-136].  
TRPM4’s activity is enhanced by decavanadate and BTP2 [137, 138]. 
TRPM4’s desensitization is delayed by Mg2+-ATP, calmodulin, PIP2 or 
phosphorylation via PKC [129, 139, 140]. The channel is also activated by high 
temperature [141]. Hydrogen peroxide inhibits TRPM4 desensitization [142]. 
Intracellular nucleotides (ATP, ADP, and AMP), spermine, glibenclamide, 
flufenamic acid and 9-phenanthrol inhibit TRPM4 [143, 144]. 9-phenanthrol is the 
most specific TRPM4 inhibitor since it does not block TRPM5 or TRPM7 [145].  
TRPM4 was first characterized as a Ca2+-activated nonselective cation 
channel with three typical features such as Ca2+ activation, voltage dependency and 
monovalent cation conductance [127]. In excitable cells, TRPM4 depolarizes the 
cell membrane and facilitates VDCC opening while the opposite effect occurs in 
non-excitable cells as it decreases the driving force for Ca2+ entry via SOCs [127, 
146]. In T lymphocytes, it decreases Ca2+ signals by inhibiting SOCs and IL-2 
production [147]. TRPM4 expression is lower in T helper type 1 compared to T 
helper type 2 cells; inhibition of the channel increases Ca2+ signals, NFATc1 
nuclear localization, and IL-2 production but decreases motility in T helper type 2 
[148]. Mast cells from TRPM4 knockout mice exhibit enhanced Ca2+ entry and 
proinflammatory mediators such as leukotriene C4, D4, E4 [149, 150]. TRPM4 is 
also important for dendritic cell migration because TRPM4 knockout impairs this 
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process [151]. It is essential for umbilical cord endothelial cell migration [152]. 
TRPM4 also facilitates cell proliferation in Hela cells, a cervical cancer-derived 
cell line [132]. In excitable cells, TRPM4 stimulates myogenic vasoconstriction of 
cerebral artery myocytes as channel inhibition reduces myogenic tone and impairs 
autoregulation [153, 154]. TRPM4 is upregulated in vascular endothelium after 
hypoxia/ischemia in vitro and in vivo and channel inhibition enhances 
angiogenesis, and capillary integrity [155]. Spontaneously hypertensive rats have 
higher TRPM4 expression in ventricular cardiomyocytes compared to 
normotensive rat [156]. It contributes to the action potential in atrial and ventricular 
cardiomyocytes [157, 158]. TRPM4 prevents bradycardia because channel blockers 
decrease the action potential rate in the sinus node [159]. Our lab characterized 
functional TRPM4 channels in pancreatic α and β cells where it facilitates VDCC 
opening to increase Ca2+ signals and glucagon and insulin secretion [146, 160]. 
TRPM4 is up-regulated after spinal cord injury and subarachnoid hemorrhage [161-
164]. TRPM4 knockout mice are hypertensive due to increased catecholamine 
secretion from adrenal chromaffin cells [131]. Hypoxia opens L-type VDCCs and 
increases intracellular Ca2+ concentration and TRPM4 activity to generate 
inspiratory bursts, synaptic drive currents in pre-Bötzinger complex [165]. The 
channel contributes to the pathogenesis of inflammation and neuronal injury in 
autoimmune encephalomyelitis and multiple sclerosis [134]. It plays a role in 
producing the slow inward cation current in cerebral Purkinje cells because TRPM4 
knockout reduces current amplitude compared to wild-type mice [135]. TRPM4 
may regulate K+ transport during endolymph formation in strial marginal cells and 
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in inner hair cells in mouse cochlea [136]. TRPM4 missense mutation is observed 
in South African Afrikaner pedigree with progressive familial heart block type 1 
[166]. Another TRPM4 mutation is observed in patients with Brugada syndrome 
[167]. 
1.4 AVP AND Ca2+ SIGNALING 
1.4.1 Structure   
The structure of AVP varies among species (Table 1.1). It is a nine amino 
acid peptide with one disulfide bond between the 1st and 6th position and Arg in the 
8th position in most species. 
1.4.2 Biosynthesis, storage and release 
AVP is synthesized in magnocellular neurons of the supraoptic and 
paraventricular nuclei as a large precursor molecule. Moreover, the synthesis is 
directed by three exons separated by two introns: exon 1 (residues 1 through 21) 
for the signal peptide AVP and N-terminal end of the neurophysin; exon 2 for the 
middle portion of neurophysin II (residues 22 through 88); exon 3 for the C-
terminal end of neurophysin II (residues 89 through 107) and a 39-residue 
glycopeptide called copeptin (Figure 1.3). After synthesis, the preprovasopressin is 
cleaved into the signal peptide and pro-vasopressin and stored into secretory 
vesicles in the Golgi apparatus, followed by splitting into AVP and neurophysin II 
[168, 169]. Neurophysin II is important for targeting, packaging and storing before 
it is released into the blood [170]. Under nerve impulses, the vesicles are 
transported down the axon via exocytosis; subsequently, AVP and neurophysin 
separate after leaving the nerve terminals [171]. In addition, AVP is synthesized in 
15 
 
other tissues such as sympathetic ganglia, heart, ovaries, adrenal gland, testis, 
thymus and pancreas [172-178]. 
Table 1.1 Structure of AVP in different species (Modified from [179].) 
 
 
Cys-Tyr-Phe-Gln-Asn-Cys-Pro-
Arg-Gly-NH2 
Arginine 
vasopressin 
(AVP) 
Most mammals 
 
Cys-Tyr-Phe-Gln-Asn-Cys-Pro-
Lys-Gly-NH2 
Lysine vasopressin 
(LVP) 
Pigs, hippos, 
warthogs, some 
marsupials 
 
Cys-Phe-Phe-Gln-Asn-Cys-Pro-
Arg-Gly-NH2 
Phenypressin Some marsupials 
 
Cys-Tyr-Ile-Gln-Asn-Cys-Pro-
Arg-Gly-NH2 
Vasotocin Non-mammals 
 
Cys-Phe-Ile-Arg-Asn-Cys-Pro-
Lys-Gly-NH2 
Lys-conopressin Great pond nail 
(Lymnaea stagnalis) 
 
Cys-Ile-Ile-Arg-Asn-Cys-Pro-
Arg-Gly-NH2 
Arg-conopressin Striated cone 
(Conus striatus) 
 
Cys-Phe-Val-Arg-Asn-Cys-Pro-
Thr-Gly-NH2 
Annetocin Red worm 
(Eisenia foetida) 
 
Cys-Leu-Ile-Arg-Asn-Cys-Pro-
Arg-Gly-NH2 
Inotocin Migratory locust 
(Locusta migratoria) 
 
1.4.3 Receptors and mechanisms of action 
AVP exerts its effect in the body by binding to three types of receptors: V1a, 
V1b and V2. AVP receptors are G-protein-coupled with seven transmembrane 
domain [180]. V1a receptors are the most prevalent in the body ranging from 
smooth muscle, mesangial cells, and lymphocytes to astrocytes [181-184]. The V1a 
receptors in humans and rats are 418 and 394 amino acids, respectively [185, 186]. 
V1b receptors are present mainly in the anterior pituitary, adrenal medulla, and 
pancreatic α and β cells [187-190] . Human and rat V1b receptors encode 424 and  
S S 
S S 
S S 
S S 
S S 
S S 
S S 
S S 
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Figure 1.3 AVP synthesis (Modified from [179].) 
 
425 amino acids, respectively and share 81% identity [187, 191]. Human V1b has 
45% and 39% homology with the V1a and V2 receptors [187]. The V2 receptor is 
found in the renal distal and principal cells of the collecting ducts [192, 193]. It is 
also found in endothelial cells and skeletal muscle of the lungs [194]. This receptor 
in humans and rats contains 371 and 370 amino acids with over 80% homology 
[192, 193, 195]. The signaling cascade via V1 receptors is by the Gq-protein-PLC-
IP3 pathway that increases intracellular Ca
2+ for a number of cellular processes 
[196, 197]. V1a receptors are linked to behavior and aggression [197]. On the other 
hand, the V1b receptor has a critical role in behavior and episodic memory [198]. 
V1a and V1b receptors are associated with food and alcohol intake, circadian 
rhythm, and thermoregulation [197]. V2 receptors are coupled to Gs proteins that 
activate the cAMP-PKA pathway and induce translocation of aquaporin-2 channels 
AVP GENE 
Transcribe 
mRNA 
Translate 
Signal 
peptide 
Vasopressin 
Neurophysin 
II  
NP Copeptin 
Neurophysin II Copeptin 
Signal 
peptide 
Vasopressin Neurophysin II Copeptin 
Vasopressin 
NP 
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for water reabsorption in the kidneys [192, 199]. Because of its effect in the 
kidneys, AVP is also called as antidiuretic hormone. The factors affecting AVP 
secretion are listed in Table 1.2. 
Table 1.2 Factors regulating AVP secretion (Modified from [179].) 
 
1.4.4 Agonists, blockers and their importance in research and clinical 
application 
 
AVP agonists and antagonists are used for treating many diseases. 
Desmopressin, an AVP analog is used to treat diabetes insipidus [200]. V1a 
antagonists are used in the treatment of ocular hypertension, congestive heart 
failure, myocardial infarction, and preterm labor. V1b antagonists improve anxiety 
and depression. V2 antagonists are used in hyponatremia, polycystic kidney 
diseases and cirrhotic ascites [201, 202].  
1.5 STATEMENT OF PROBLEMS AND SPECIFIC AIMS 
In the United States, the direct expenses of osteoporotic fractures are 
estimated to be around $18 billion each year [203]. In addition, the total cost related 
Stimulation Inhibition 
Major factors 
Hyperosmolality 
Hypovolemia 
Hypotension 
Hypoosmolality 
Hypervolemia 
Additional factors 
Cerebrospinal fluid sodium increase 
Nausea, vomiting  
Stressor, lactation 
Hyperthermia 
Ageing 
Hypothermia 
α-adrenergic agonists 
γ-aminobutyric acid 
Alcohol 
Cortisol 
Iodothyronines 
Atrial natriuretic peptide 
Drugs: Nicotine, Opiates, Barbiturates, 
Sulfonylureas, Antineoplastic agents, 
Neurosteroids 
Apelin 
AVP 
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to adolescent obesity is estimated to be $254 billion [204]. Therefore, 
understanding the mechanisms controlling osteogenesis and adipogenesis from 
stem cells is important for bone healing and obesity prevention. However, there is 
limited information regarding the effects of Ca2+ signaling on stem cell 
differentiation. Calcium oscillations stimulate transcription factors and gene 
expression [205]. They are important for the G1/S phase of the cell cycle and 
originate from IP3-mediated Ca
2+ release from the ER in ESCs and BMSCs [83, 
85]. In addition, they are observed during stem cell differentiation but cease at the 
end of this process [84, 206]. Physical manipulation of Ca2+ oscillations increases 
osteogenesis in hBMSCs [207]. As a result, the overall goal of this dissertation is 
to investigate the effect of TRPM4 and AVP on Ca2+ signaling for controlling stem 
cell differentiation. Currently, there are no reports of TRPM4 in any type of stem 
cell. Therefore, we hypothesize that TRPM4 is a critical regulator of Ca2+ signaling 
and stem cell differentiation. Our first aim is determine the role of TRPM4 in 
rDFSCs (Chapter 2) and hASCs (Chapter 3). Furthermore, AVP induces 
myogenesis and T cell differentiation via V1 receptors; however, there is no 
information in hASC differentiation [182, 208]. Our lab found that AVP increases 
intracellular Ca2+ concentration in hASCs. Consequently, we hypothesize that 
hASCs have AVP receptors which are involved in Ca2+ signaling and adipogenic 
differentiation. Our second aim is to characterize the mechanism by which AVP 
increases intracellular Ca2+ and its role in adipogenesis in hASCs (Chapter 4).  
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CHAPTER 2: TRANSIENT RECEPTOR POTENTIAL 
MELASTATIN 4 CHANNEL CONTROLS CALCIUM 
SIGNALS AND DENTAL FOLLICLE STEM CELL 
DIFFERENTIATION* 
 
2.1 INTRODUCTION 
Stem cell therapy offers a promising approach in providing an advanced and 
reliable therapeutic strategy for tissue regeneration and disease treatment. 
However, fundamental processes controlling the fate of stem cells are not well 
understood. Dental follicle stem cells (DFSCs) are derived from the neural crest 
and give origin to the periodontal ligament (PDL) [1, 2]. These cells are multipotent 
and can differentiate into various cell types including osteoblasts, adipocytes, and 
neurons [3]. In addition, they can be easily obtained from extracted third molars 
that are usually discarded as medical waste. Therefore, DFSCs represent an 
alternative source of stem cells for tissue regeneration. The transient receptor 
potential (TRP) proteins are a family of ion channels initially identified in the 
Drosophila melanogaster visual system [4]. Despite intensive research, 
information regarding their function in stem cells remains largely unknown. The 
melastatin subfamily of TRP channels is composed of eight members (transient 
receptor potential melastatin [TRPM1–8]), with TRPM4 and TRPM5 being the 
only non-calcium conducting channels [5, 6]. Both are permeable mainly to Na+, 
resulting in depolarization upon channel activation. The ability of TRPM4 to 
depolarize cells transforms the normal intracellular Ca2+ oscillations into sustained  
* Reprinted with permission from John Wiley and Sons Inc. Authors: Piper Nelson, 
Tran Doan Ngoc Tran, Hanjie Zhang, Olga Zolochevska, Marxa Figueiredo, Ji-
Ming Feng, Dina L. Gutierrez, Rui Xiao, Shaomian Yao, Arthur Penn, Li-Jun 
Yang and Henrique Cheng. Stem Cells. 2013;31:167–177. 
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Ca2+ increases in T lymphocytes [7]. This is due to a decrease in the driving force 
for Ca2+ entry via store-operated Ca2+ channels (SOCs), the main pathway for Ca2+ 
entry in nonexcitable cells, such as DFSCs of mesenchymal origin [3]. Of the 
TRPMs, only the TRPM7 has been reported in stem cells. It is essential for bone 
marrow-derived mesenchymal stem cell (MSC) proliferation and survival and is 
required for early embryonic development [8, 9].  
Oscillations in the intracellular Ca2+ concentration ([Ca2+]i) are commonly 
observed during stem cell differentiation, and there is evidence that they may 
control the differentiation process. Physical manipulation of Ca2+ signals with 
noninvasive electrical stimulation enhances Ca2+ entry and osteodifferentiation of 
human MSCs (hMSCs; [10]). That study suggests that increased Ca2+ entry is a 
result of activation of G protein-coupled receptors and the opening of 
Ca2+ channels. In addition, activation of gene transcription by nuclear factor of 
activated T-cells (NFAT) in immune cells appears to be controlled by the shape and 
frequency of the Ca2+ signals [7, 11]. Interestingly, both Ca2+ signals and NFAT-
activated gene transcription disappear at the completion of adipogenesis in hMSCs 
[12]. Similar observations have been made during the terminal stages of osteoblast 
differentiation [10], implying that Ca2+ signals may be important for directing and 
terminating the process. Furthermore, oscillations in the [Ca2+]i control the 
transition from the G1 phase to the S phase of the cell cycle to preserve embryonic 
stem cell (ESC) pluripotency [13]. Therefore, the question of how Ca2+ signals 
control stem cell differentiation is fundamentally important.        
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The TRPM4 channel is a widely expressed protein present in both  
electrically excitable and nonexcitable cells. Patch-clamp recordings revealed that 
it is a Ca2+-activated nonselective cation (CAN) channel, inhibited by nucleotides 
and polyamines [5, 14]. Although not permeable to Ca2+, TRPM4 has a significant 
impact on Ca2+ signals because it provides a mechanism that allows cells to 
depolarize in a Ca2+-dependent manner. In nonexcitable cells such as 
undifferentiated stem cells, TRPM4-mediated depolarization decreases the driving 
force for Ca2+ entry through SOCs, whereas in excitable cells (e.g., neuron, 
endocrine, or cardiac muscle), TRPM4 has the opposite effect by providing the 
depolarization necessary for the opening of voltage-dependent Ca2+ channels. 
Previous studies identified SOCs in hMSCs and mESCs [15, 16]. In fact, molecular 
suppression of TRPM4 increases both Ca2+ entry via SOCs and interleukin 2 (IL-
2) production in nonexcitable T lymphocytes [7]. Studies in excitable cells revealed 
a significant reduction in insulin secretion during glucose stimulation in pancreatic 
β-cells after TRPM4 knockdown [17]; this reduction results from a decrease in the 
magnitude of the Ca2+ signals [18]. A similar observation was made in glucagon 
secreting α-cells [19]. In addition to the effects in immune and islet cells, the control 
of Ca2+ signals by TRPM4 is critical for myogenic constriction of cerebral arteries, 
migration of dendritic cells, and cardiac function [20–22]. Given the importance of 
Ca2+ signals for stem cell differentiation, it is possible that ion channels such as 
TRPM4 could be involved in their regulatory mechanism. 
In this study, we investigated the role of TRPM4 in differentiation of rat 
DFSC, a MSC from the first molar tooth. We examined TRPM4 gene expression 
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by reverse transcriptase polymerase chain reaction (RT-PCR) and tested whether 
currents with the characteristics of those known for this channel could be detected 
using the patch-clamp technique. To gain insight into TRPM4 function, we 
generated stable knockdown cells via short hairpin RNA (shRNA). These cells 
were then used in cell proliferation, Ca2+ imaging analysis, and differentiation 
experiments. Finally, we performed whole genome microarray analysis to examine 
potential genes regulated by TRPM4 during DFSC differentiation. 
2.2 MATERIALS AND METHODS 
2.2.1 Reagents 
 All reagents were purchased from Sigma-Aldrich (St. Louis, MO, 
http://www.sigmaaldrich.com), except for fura-2 acetoxymethyl ester (Fura-2AM), 
which was from Molecular Probes (Eugene, OR, http://probes.invitrogen.com). 
2.2.2 Cell culture 
 DFSCs of the first mandibular molar were harvested from Sprague–Dawley 
rat pups 5–7 days postnatal and cultured according to published methods [23]. Cells 
were grown in α-minimum essential medium (MEM) supplemented with 20% FBS 
and aerated with 5% CO2 and 95% air at 37°C. Experiments were performed with 
cells from passages 2 through 8. MC3T3-E1 preosteoblast cells were grown in α-
MEM supplemented with 10% fetal bovine serum (FBS) and cultured as described 
for DFSCs. Human adipocyte stem cells (hACSs) were maintained in Dulbecco's 
modified Eagles medium (DMEM)/Ham's F-12 medium (Sigma-Aldrich) with 
10% FBS and aerated with 5% CO2 at 37°C. All experiments were performed with 
cells from passages 6 through 8. 
43 
 
2.2.3 Induction and detection of cell differentiation 
2.2.3.1 Osteogenesis 
Cells were induced with osteogenic medium, consisting of DMEM-LG 
supplemented with 10% FBS, 10 nM dexamethasone, 0.1 mM ascorbic-acid-2-
phosphate, and 10 mM β-glycerophosphate. The medium was changed every 4 days 
during osteogenesis. After a 14-day period, the medium was aspirated, and the 
cultures were washed twice with phosphate buffered saline (PBS), fixed with 10% 
formaldehyde, washed again with distilled water, and incubated with 1% Alizarin 
Red S (ARS) in dH2O. After incubation, the staining solution was removed, and the 
cultures were washed with distilled water to remove excess dye. Stained 
monolayers were visualized by phase contrast microscopy with an inverted 
microscope (Zeiss, Thornwood, NY, http://microscopy.zeiss.com). 
2.2.3.2 Adipogenesis 
 Cells were induced with adipogenic medium containing DMEM-LG 
supplemented with 10% FBS, 50 μg/ml ascorbic acid, 0.1 μM dexamethazone, and 
50 μg/ml indomethacin. Adipogenesis was determined by oil red O (ORO) staining. 
Briefly, cells were washed with PBS, fixed with 10% formalin for 10 minutes, 
washed twice with dH2O, and incubated with 60% isopropanol for 5 minutes. Cells 
were then stained with ORO solution for 5 minutes and washed again to remove 
excess dye. The presence of lipid droplets was visualized by phase contrast 
microscopy with an inverted microscope. 
2.2.4 RT-PCR 
 RNA was extracted from DFSCs, hASCs, MC3T3-E1 cells, and bone tissue 
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using the RNAqueous-4PCR kit according to manufacturer's instructions (Ambion, 
Austin, TX, http://www.ambion.com). The RNA was purified with DNase 1 
treatment. Reverse transcription was performed with MMLV-Reverse 
Transcriptase. PCR was performed with Ambion's RETROscript kit and rat primers 
with the sequences listed (forward/reverse [5′–3′]): TTGGCATACTGGGAGACG 
CA/GGCCCAAGATCGTCATCGT (TRPM4; 301 bp); CAAGTGTGACATGGT 
GGCCATCTT/GCTCAGGTGGCTGAGCAGGAT (TRPM5; 600 bp); GCAAAT 
GACTCCACTCTC/GATTCTCTCTTCACTCCCAG (TRPM7; 422 bp). Rat 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (420 bp) and ultrapure 
water were used as positive and negative controls, respectively. The human primers 
(forward/reverse [5′–3′]) were: AGCATGGTGCCGGAGAA/GGTGTCTCTATT 
CCGGACCACA (TRPM4; 600 bp); CAGAACATCACCTCACACCAG/GGTT 
CTCGCTCTTCTGGTTC (TRPM5; 640 bp); TGAAACGAGTGAGTTCTCTTG 
CTG/CACAGGTGTAAATGGAATGCTC (TRPM7; 309 bp); AACAGCGACAC 
CCACTCCTC/GGAGGGGAGATTCAGTGTGGT (GAPDH; 258 bp). 
2.2.5 Electrophysiology 
 Cells were maintained in standard modified Ringer's solution of the 
following composition (in mM): NaCl 140, KCl 2.8, CaCl2 1, MgCl2 2, glucose 4, 
HEPES-NaOH 10, pH 7.2 adjusted with NaOH. The standard internal solution 
contained (in mM): Cs-glutamate 120, NaCl 8, MgCl2 1, Cs-BAPTA 10, HEPES-
CsOH 10, pH 7.2 adjusted with CsOH. The internal solution's buffered 
Ca2+ concentration was adjusted as necessary with CaCl2 (calculated with 
WebMaxC http://www.stanford.edu/∼cpatton webmaxcS.htm/). The Na+-free 
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modified Ringer's solution contained (in mM): choline-Cl 140, KCl 2.8, CaCl2 1, 
MgCl2 2, glucose 4, HEPES-CsOH 10, pH 7.2 adjusted with CsOH. The osmolarity 
of the solutions were approximately 300 mOsm/L. TRPM4 currents were recorded 
in the tight-seal whole-cell configuration mode at 21°C–25°C. High-resolution 
current recordings were acquired by a computer-based patch-clamp amplifier 
system (EPC-10, HEKA, Lambrecht, Germany, http://www.heka.com). Patch 
pipettes had resistances of 4–7 MΩ and were coated in Sigmacote silicon solution 
(Sigma-Aldrich). Immediately following establishment of the whole-cell 
configuration, voltage ramps of 50 millisecond duration spanning the voltage range 
of −100 to +100 mV at a rate of 0.5 Hz over a period of 300–600 seconds. All 
voltages were corrected for a liquid junction potential of 10 mV between external 
and internal solutions, calculated with Igor PPT Liquid Junction Potential software 
(Wavemetrics, Portland, OR, http://www.wavemetrics.com). 
2.2.6 Generation of TRPM4 knockdown cells 
 Lentivirus plasmids were obtained from Sigma-Aldrich in a pLKO.1 
backbone and contained either nonspecific control (SHC002) or TRPM4-specific 
shRNA (SHDNA-NM_175130, TRCN0000068684 and TRCN0000068686) under 
the control of the U6 promoter, plus the puromycin resistance and green fluorescent 
protein (GFP) reporter genes. Cells were selected in 1 μg/mL puromycin for 1 
week, and transduction efficiency was determined by FACScan flow cytometry 
(BD Biosciences, Franklin Lakes, NJ, http://www.bdbiosciences.com) to sort GFP+ 
cells. Stably transduced cells were used for functional experiments. 
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2.2.7 Cell proliferation assay 
An (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) 
assay was used to compare the proliferation rates between control and TRPM4 
knockdown cells. One week following lentiviral transduction 104 cells per well 
were seeded into three 96-well plates and cultured in normal growth medium for 3 
days. Cells were then placed in osteogenic or adipogenic medium and analyzed by 
an MTT-based assay kit (Bioassay Systems, Hayward, 
CA, http://www.bioassaysys.com) at 48, 72, and 96 hours. MTT solution was added 
to each well and incubated at 37°C for 4 hours. Then, solubilization buffer was 
added to dissolve the insoluble formazan product. The absorbance at 550 nm was 
measured with an Ultramark Microplate Imaging System (BioRad, Hercules, 
CA, http://www.bio-rad.com). Cell proliferation was expressed as the absorbance 
of the cells minus the background. 
2.2.8 Calcium imaging analysis 
Cells were loaded with 5 μM Fura-2AM for 30 minutes at 37°C. A Ca2+-
imaging buffer containing (in mM) NaCl 136, KCl 4.8, CaCl2 1.2, MgSO4 1.2, 
HEPES 10, glucose 4, and 0.1% BSA at a pH of 7.3 was used for Fura-2AM loading 
and perfusion throughout imaging experiments. Calcium measurements were 
obtained with a dual excitation fluorometric imaging system (TILL-Photonics, 
Gräfelfingen, Germany, http://www.till-photonics.com) controlled by TILLvisION 
software. Fura-2AM-loaded cells were excited by wavelengths of 340 nm and 380 
nm. Fluorescence emissions were sampled at a frequency of 1 Hz and computed  
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into relative ratio units of the fluorescence intensity of the different wavelengths 
(F340/F380). 
2.2.9 Alkaline phosphatase activity 
Quantification of alkaline phosphatase (ALP) enzyme activity at different 
time points during osteogenesis was made with an ALP assay kit (BioChain, 
Newark, CA) according to the manufacturer's instructions. Differentiation 
experiments were performed in quadruplicate in a 24-well plate (four wells per time 
point) and repeated three times. The cells were washed in PBS and lysed with 0.5 
ml 0.2% Triton X-100 in distilled water prior to ALP activity determination. 
Samples were assayed in duplicate in a 96-well plate and analyzed at 405 nm with 
a microcount plate reader BS10000 (PerkinElmer, Waltham, 
MA, http://www.perkinelmer.com). 
2.2.10 Microarray analysis 
Raw/normalized intensity values and the log-ratios of all possible pairwise 
comparisons were preprocessed by the microarray manufacturer (PhalanxBio Inc., 
Belmont, CA, http://www.phalanxbiotech.com). The genes that were associated 
with osteogenesis or adipogenesis and affected by TRPM4 knockdown were 
selected based on the following two criteria: first, genes displaying at least twofold 
upregulation/downregulation during cell differentiation in either cell population 
(minimum absolute fold-change ≥2 between control cells prior to differentiation 
[C0] and after 14 days [C14] and between TRPM4 knockdown cells prior to 
differentiation [KD0] and after 14 days [KD14]). Second, fold change differences 
in genes exhibiting differential upregulation/downregulation between control and 
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knockdown cell populations during cell differentiation (i.e., differences that exist 
between fold-change values found in control and knockdown cells). 
Following gene selection, we identified the biological functions that are 
most significantly associated (p < .05) with selected gene sets via Ingenuity 
Pathway Analysis (IPA 9.0, Ingenuity Systems, Redwood City, 
CA, http://www.ingenuity.com). A right-tailed Fisher's exact test was used to 
calculate a p-value, determining the probability that each biological function 
assigned to that gene set is due to chance alone. Gene networks were created with 
Ingenuity pathway designer. 
2.2.11 Data analysis 
 Patch-clamp recordings are shown as means + SEM and were plotted with 
Igor Pro 5 software program (Wavemetrics). The optical density (OD) values from 
control and TRPM4 knockdown groups in the MTT and ALP assays are shown as 
means + SEM and were compared by a two-tailed, unpaired Student's t-test for each 
time point. Statistical significance was established at p<.05. 
2.3 RESULTS 
2.3.1 DFSCs express TRPM4 and differentiate into osteoblasts and adipocytes 
First, we used RT-PCR analysis to determine whether DFSCs expressed the 
TRPM4 gene. We identified TRPM4 expression with the predicted molecular size 
(301 bp) but not the TRPM5 (600 bp), a closely related channel with similar 
function (Figure 2.1,A). We also confirmed TRPM4 expression in murine 
preosteoblast MC3T3-E1 cells and rat mandible and tibia bones. Both cells and 
bone tissues expressed the TRPM7 (422 bp), which is required for cell proliferation 
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and viability [8, 24]. In order to investigate whether stem cells of human origin 
expressed TRPM4, we performed RT-PCR with RNA extracted from hASCs. We 
identified similar gene expression pattern as the one observed with DFSCs 
(Figure 2.1,A). To demonstrate the multipotency of DFSCs, we tested their 
differentiation capability into osteoblasts and adipocytes determined by ARS and 
ORO staining at the end of 14 days (Figure 2.1,B). These stem cells were capable 
of differentiation into the respective cell types as indicated by extracellular matrix 
mineralization and lipid droplet accumulation. The adipogenic potential of hASCs 
is shown in Figure 2.1,B. 
 
Figure 2.1 TRPM4 gene expression and multipotency of dental follicle stem 
cells. (A): Total RNA isolated from rat DFSCs, mandible, and tibia bones, mouse 
preosteoblast MC3T3-E1 cells, hASCs and reverse-transcribed into cDNA. 
Reverse transcriptase polymerase chain reaction was performed with specific 
TRPM4 and TRPM5 primers. TRPM7 and GAPDH primers served as positive 
controls. (B): The multipotency of DFSCs was confirmed after 14 days in 
osteogenic (upper panel) and adipogenic (lower panel) differentiation medium with 
Alizarin Red S and oil red O staining. The adipogenic potential of hASCs is also 
shown. Note the presence of mineralization in the extracellular matrix as well as 
lipid droplet accumulation at ×32 magnification. Abbreviations: GAPDH, 
glyceraldehyde 3-phosphate dehydrogenase; hASC, human adipocyte stem cells; 
rDFSC, rat dental follicle stem cells; TRPM4, transient receptor potential 
melastatin 4. 
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2.3.2 DFSCs have functional TRPM4 channels 
 Next, we performed electrophysiological recordings to investigate the 
biophysical properties of TRPM4, which is activated by increases in [Ca2+]i [5]. We 
performed whole-cell patch-clamp recordings during perfusion of DFSCs with 
buffered Ca2+ concentrations ranging from 0.1 to 3 μM at 0 mV holding potential 
(Figure 2.2,A). These experiments resulted in a concentration-dependent activation 
of TRPM4 currents with an EC50 of 0.94 μM and Hill coefficient of 7.79 
(Figure 2.2,C, 2.2,D). The current–voltage relationships (I/V) that are the signature 
of an ion channel are typical of those reported for TRPM4 (Figure 2.2,B). Perfusion 
of hASCs with increasing buffered Ca2+ concentrations (0.1–3 μM) also resulted in 
a concentration-dependent activation of currents and I/V similar to those described 
for channel (Figure 2.2,E, 2.2,F). In addition to Ca2+ activation, TRPM4 is voltage- 
dependent, where negative potentials inhibit and positive potentials increase its 
open probability [5, 25]. We tested the effect of −60 mV, 0 mV, and +60 mV 
holding potentials on TRPM4 currents with 1 μM buffered Ca2+. Patch-clamp 
recordings at negative potentials suppressed and at positive potentials increased the 
current amplitude compared to 0 mV (Figure 2.3,A). The effect of voltage on 
TRPM4 is shown by the I/V from representative cells (Figure 2.3,B). The opening 
of TRPM4 results in Na+ entry into cells and depolarization. Hence, we examined 
channel conductivity by replacing NaCl in the extracellular solution with choline 
chloride. Under this condition, inward currents were completely abolished 
compared to cells maintained in NaCl solution during experiments with 1 μM 
buffered Ca2+ and +60 mV holding potential (Figure 2.3,C). The replacement of 
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Na+ caused a noticeable shift in the reversal potential due to hyperpolarization 
(Figure 2.3,D; black arrow).                                        
 
Figure 2.2 Calcium-dependent activation of transient receptor potential melastatin 
4 (TRPM4) currents in dental follicle stem cells. (A): Average inward and outward 
currents during perfusion with increasing buffered Ca2+concentrations. Traces 
represent the mean + SEM (n = 5–8 cells per concentration) recorded at 0 mV 
holding potential. (B): Current–voltage relationship (I/V) under experimental 
conditions described in (A) taken from representative cells at 300 second for each 
Ca2+ concentration. (C): Average inward currents (mean + SEM) from cells 
represented in panel (A). (D): A dose-response analysis revealed an EC50 of 0.94 
μM and Hill coefficient of 7.79. (E): Average inward and outward currents during 
perfusion of human adipocyte stem cells with increasing buffered 
Ca2+ concentrations. Traces represent the mean + SEM (n = 3–6 cells per 
concentration) recorded at 0 mV holding potential. (F): Current–voltage 
relationship (I/V) under experimental conditions described in (E) taken from 
representative cells at 600 second for each Ca2+ concentration. 
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Figure 2.3 Voltage dependency and ionic conductivity of transient receptor 
potential melastatin 4 (TRPM4) in dental follicle stem cells (DFSCs). (A): Average 
inward and outward currents in response to 1 μM Ca2+ at +60 mV, 0 mV, and −60 
mV holding potentials. Traces are mean + SEM (n = 5–6 cells per holding 
potential). (B): Current–voltage relationship (I/V) under experimental conditions 
described above at 600 s from representative cells. (C): Average inward and 
outward currents from DFSCs maintained in NaCl solution compared to cells kept 
in extracellular buffer with choline-Cl replacing NaCl. Traces are mean + SEM (n = 
6–12 cells). (D): Current–voltage relationship (I/V) taken at 600 second from a 
representative cell. Note the shift in reversal potential (arrow) and 
hyperpolarization caused by the lack of Na+ entry with choline-Cl substitution. 
 
2.3.3 Molecular suppression of TRPM4 inhibits channel activity and cell 
proliferation 
 
To investigate the functional significance of TRPM4 in DFSCs, we used 
shRNA and a lentiviral vector to generate stable TRPM4 knockdown cells. We 
confirmed the effectiveness of the shRNA by performing patch-clamp recordings 
with 1 μM buffered Ca2+ and 0 mV holding potential (HP) to activate the channel. 
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TRPM4 currents were significantly reduced in knockdown cells compared to 
control shRNA (Figure 2.4,A) and confirmed by the I/V (Figure 2.4,B). In stem 
cells, a decrease in cell proliferation is required prior to differentiation [26, 27]. 
Therefore, we used the MTT assay to examine whether cell proliferation was 
impacted by TRPM4 during osteogenesis and adipogenesis. Inhibition of TRPM4 
significantly decreased cell proliferation compared to control shRNA cells during 
a 96-hour period when placed in osteogenic medium (Figure 2.4,C). Under 
adipogenic conditions, there was a reduction in cell proliferation only during the 
initial 48 hours with TRPM4 knockdown (Figure 2.4,D). Based on these results, we 
reasoned that if cell proliferation decreased during osteogenesis, there was a 
possibility that TRPM4 suppression would facilitate osteoblast but not adipocyte 
differentiation. 
2.3.4 TRPM4 inhibits osteogenesis but facilitates adipogenesis 
In order to test TRPM4's function on DFSC differentiation, we cultured cells 
in osteogenic and adipogenic media over 21 days and performed ARS and ORO 
staining on days 0, 7, 14, and 21. Inhibition of TRPM4 with two different sets of 
shRNAs (I and II) enhanced mineralization of DFSCs under osteogenic conditions 
compared to control shRNA cells, as determined by ARS staining (Figure 2.5,A). 
Furthermore, DFSCs cultured under adipogenic conditions failed to differentiate 
into adipocytes, as indicated by the absence of ORO staining (Figure 2.5,B). These 
results suggest that TRPM4 inhibits osteogenesis but is required for or at least 
facilitates adipogenesis. 
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Figure 2.4 TRPM4 knockdown and its impact on cell proliferation. (A): Average 
inward and outward currents from control shRNA (n = 9) and TRPM4 shRNA cells 
(n = 6) recorded at +60 mV holding potential and 1 μM buffered Ca2+. A noticeable 
reduction in current amplitude is seen with TRPM4 knockdown. Traces represent 
mean + SEM. (B): Current–voltage relationship (I/V) obtained from representative 
cells at 300 s. (C, D): The effect of TRPM4 knockdown on cell proliferation was 
examined by MTT assay. A significant decrease in cell proliferation was observed 
in TRPM4 shRNA cells compared to control shRNA at all time points under 
osteogenic but not adipogenic conditions. Data are shown as mean + S.E.M. (n = 6 
wells/time point); *, p < .05. Abbreviations: MTT, (3-(4,5-Dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide; TRPM4, transient receptor potential melastatin 
4; shRNA, short hairpin RNA. 
2.3.5 TRPM4 controls Ca2+ signals and ALP enzyme activity 
 Calcium oscillations are linked to stem cell differentiation, and TRPM4 is 
key regulator of Ca2+ signaling in different cell types [7, 18, 19, 12]. Therefore, we 
performed real-time Ca2+ imaging analysis to determine its impact on Ca2+ signals  
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Figure 2.5 Molecular suppression of TRPM4 enhances osteogenesis but inhibits 
adipogenesis. (A): Extracellular matrix mineralization shown by Alizarin Red S 
staining during a 21-day period in control shRNA and TRPM4 shRNA 
cells. (B): Lipid droplet accumulation during a 21-day period in control shRNA and 
TRPM4 shRNA cells after Oil Red O staining. Suppression of TRPM4 enhanced 
mineralization during osteogenesis but inhibited lipid droplet accumulation during 
adipogenesis. Images are representative of three different experiments (×10 
magnification). Abbreviations: TRPM4, transient receptor potential melastatin 4; 
shRNA, short hairpin RNA. 
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generated by ATP, which influence stem cell differentiation [28, 29]. Stimulation 
of control shRNA cells with 100 µM ATP resulted in the typical increase in 
[Ca2+]i characterized by a first phase due to Ca
2+ release from the ER, followed by 
a secondary phase due to Ca2+ influx via SOCs (Figure 2.6,A). TRPM4 knockdown 
transformed the biphasic Ca2+ pattern into a gradual and sustained increase 
(Figure 2.6,B). The average responses of cells from three different cell passages are 
shown in Figure 2.6,C. The proliferation and osteogenic differentiation assays 
combined with the Ca2+ signaling data prompted us to investigate whether enhanced 
osteoblast differentiation and mineralization in knockdown cells were associated 
with an increase in ALP enzyme activity. This enzyme is one of the hallmarks for 
osteogenesis [30]. We found that there was also a significant increase in ALP 
enzyme activity on days 14 and 21 of osteoblast differentiation compared to control 
shRNA cells (Figure 2.6,D). 
2.3.6 Genes regulated by TRPM4 during osteogenic and adipogenic 
differentiation 
 
 Finally, we used whole genome microarray analysis to investigate potential 
genes controlled by TRPM4 during 14 days of differentiation. Based on the 
approach described for microarray analysis, we first examined genes involved in 
osteogenesis because of the enhancement of mineralization and osteoblast 
formation with TRPM4 knockdown. We identified four genes involved in bone 
mineralization (nuclear factor erythroid-derived 2 [NFE2], asporin [ASPN], matrix 
extracellular phosphoglycoprotein [MEPE], and matrix γ-carboxyglutamate protein 
[MGP]). All four genes were upregulated (MEPE 11-fold; MGP 8.6-fold; NFE2 
1.9-fold) compared to control shRNA cells, while ASPN gene expression was 37.4- 
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Figure 2.6 TRPM4 regulates Ca2+ signals and increases ALP enzyme activity. 
(A): Calcium signals from single control shRNA cells in response to 100 μM 
ATP. (B): Same experiment as in (A), except with TRPM4 shRNA cells. (C): 
Average Ca2+ signals from control shRNA (n = 47 cells) and TRPM4 knockdown 
(n = 64 cells) from three different experiments. (D): ALP enzyme activity during a 
21-day period under osteogenic differentiation conditions. Results are presented as 
mean + SEM from three different experiments (n = 4 wells per time point); *, p < 
.05. Abbreviations: ALP, alkaline phosphatase; TRPM4, transient receptor 
potential melastatin 4; shRNA, short hairpin RNA. 
 
fold higher in controls than knockdown cells (Figure 2.7,A). We also identified four 
genes involved in osteoblast differentiation (Cbp/p300-interacting transactivator 1 
[CITED1], cyclin-dependent kinase 6 [CDK6], c-fos induced growth factor [FIGF], 
and IL 6 receptor [IL6R]). Both CITED1 and CDK6 genes were downregulated 
1.5- and 0.9-fold in controls compared to TRPM4 shRNA cells, whereas FIGF and 
IL6 were upregulated twofold and 0.7-fold, respectively (Figure 2.7,A). In addition, 
we found the bone development gene, Lumican (LUM), upregulated 12.6-fold with 
TRPM4 suppression. Furthermore, our results indicated that TRPM4 knockdown 
inhibited adipogenesis. We identified eight genes: Lipin 1 (LPIN1), tribbles 
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homolog 3 (TRIB3), WNT inhibitory factor 1 (WIF1), secreted frizzled-related 
protein 1 (SFRP1), matrix metallopeptidase 3 (MMP3), selenium binding protein 1 
(SELENBP1), aldehyde dehydrogenase 6 family member A1 (ALDH6A1), and 
regulator of G-protein signaling 2 (RGS2) involved in this process (Figure 2.7,B). 
Of the eight, the TRIB3 was the only gene downregulated, with a 24.7-fold 
reduction in knockdown compared to control cells. From the upregulated genes, 
SFRP1 (10.8-fold) and RGS2 (onefold) expression were higher in control cells. 
TRPM4 suppression increased LPIN1 (3.7-fold), WIF1 (1.3-fold), MMP3 (22.9-
fold), SELENBP1 (3.2-fold), and ALDH6A1 (1.4-fold) over control cells. The 
genes involved in brown fat differentiation are shown in the diagram (Figure 2.7,B). 
2.4 DISCUSSION  
The study describes for the first time the expression and functions of 
TRPM4 in stem cells. Using rat DFSCs, we identified TRPM4 gene expression and 
currents typical for the channel, which were Ca2+-dependent, voltage sensitive, and 
conducted mainly Na+. Perfusion of cells with increasing Ca2+ concentrations 
resulted in the activation of TRPM4 with an EC50 of 0.94 μM and Hill coefficient 
of 7.79. This is consistent with previous findings in pancreatic α and β cells [19]; 
thus it appears that in DFSCs, TRPM4 is more sensitive to changes in [Ca2+]i. The 
TRPM4 channel also exhibited a strong voltage dependency with currents 
suppressed at negative and facilitated at positive holding potentials [5, 25]. These 
currents were mainly due to Na+ entry into cells, as prior to performing functional 
studies. Under both conditions, we were able to identify mineralization and lipid 
droplet accumulation after 14 days.  
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To investigate the role of TRPM4 in DFSC differentiation, we generated 
stable knockdown cells with shRNA and a lentiviral vector. We selected this 
approach because of concern over loss of knockdown effect with transient 
transfection during differentiation. Inhibition of TRPM4 was confirmed with 
elevated Ca2+ concentration and+60 mV holding potential that resulted in a 
significant reduction in current amplitude. In DFSCs, inhibition of TRPM4 did not 
cause cell death, which is similar to findings in knockout mice [31, 32], suggesting 
that TRPM4 is not lethal. With the availability of the knockdown cells, we 
examined TRPM4's impact on proliferation and differentiation. A decrease in stem 
cell proliferation is a prerequisite for osteogenesis and adipogenesis [26, 27]. The 
fact that TRPM4 suppression decreased DFSCs proliferation during the initial 96 
hours of osteogenesis, but not of adipogenesis, indicated a possible enhancement 
of osteoblast differentiation. This hypothesis was supported by the increased 
mineralization and ALP enzyme activity; however, under adipogenic conditions, 
DFSCs failed to differentiate into adipocytes. These findings suggest that TRPM4 
functions as an inhibitor of osteogenesis, while it is required and/or facilitates 
adipogenesis. 
Calcium oscillations are often present during stem cell differentiation and 
are linked to the differentiation process by activating specific transcription factors 
[12, 13]. To provide insights into the mechanism controlling DFSC differentiation, 
we investigated their Ca2+ signaling pattern of DFSCs during agonist stimulation. 
Inhibition of TRPM4 transformed the normal ATP-induced biphasic Ca2+ pattern, 
characterized by a sharp increase (ER release–first phase) followed by influx 
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(Ca2+ entry via SOCs–secondary phase) and then a gradual increase followed by a 
sharp decrease. This was unexpected and different from observations in T 
lymphocytes, which also use SOCs as the main Ca2+ entry pathway. TRPM4 
suppression in immune cells results in a sustained secondary phase without 
impacting the first phase and increases IL-2 production via the calcineurin-NFAT 
pathway [7, 11]. It is possible that in DFSCs there could be direct interaction 
between TRPM4 and the ER to control the rate of Ca2+ release and refill. Such 
relationship between ER proteins (e.g., stromal interaction molecule 1) and ion 
channels (e.g., SOCs) are essential for Ca2+ signaling in nonexcitable cells [33, 34]. 
Another possibility is that of TRPM4 multimerization with SOCs to control the rate 
of Ca2+ influx. Several TRP members are capable of homomultimerization and 
heteromultimerization [35–38]. However, the gradual increase in [Ca2+]i with 
TRPM4 suppression suggests a regulatory mechanism between TRPM4 and the 
ER. Further studies will be required to elucidate the mechanism underlying the 
control of Ca2+ signals by TRPM4 in DFSCs. 
Functional studies in different cell types provide a direct link between 
TRPM4, Ca2+ signaling, and cellular responses. Together, they control dendritic 
cell migration and cytokine production in T lymphocytes [7, 11, 21]. They also 
regulate insulin and glucagon secretion from pancreatic islet cells and myogenic 
constriction in cerebral arteries [18–20]. Because gene transcription is one of the 
downstream events regulated by TRPM4, we performed whole genome microarray 
analysis to identify potential genes responsible for the enhancement of osteogenesis 
and inhibition of adipogenesis. We identified four genes involved in osteoblast 
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differentiation (CITED1, CDK6, FIGF, IL6R) and four in bone mineralization 
(NFE2, ASPN, MEPE, MGP). Comparison between osteogenic differentiation 
genes from control and knockdown cells revealed a maximum of twofold 
differences, whereas for bone mineralization, the MEPE and MGP genes were 
upregulated 11- and 8.6-fold with TRPM4 suppression. These findings are 
consistent with studies in human dental pulp and murine preosteoblast cells, where 
MEPE expression enhances osteoblast differentiation and mineralization via the 
BMP-2 signaling pathway [39, 40]. Although the role of MGP in dental tissue is 
unclear, studies in knockout mice show increased mineralization of pulmonary and 
renal arteries via the BMP-4 pathway [41]. This is contrary to our observation in 
DFSCs. Perhaps the differences in signaling pathway and tissues affected by MGP 
expression could account for this disparity. In fact, the BMP-2 pathway is reported 
to control DFSC differentiation into osteoblasts [42]. Furthermore, TRPM4 
knockdown inhibited ASPN expression 39.4-fold over control cells. This is relevant 
to DFSCs because this gene is predominantly expressed in the PDL and in dental 
follicle cells that give rise to the ligament [43]. Since ASPN expression inhibits 
differentiation and mineralization of the PDL [43], its suppression by TRPM4 
knockdown may have contributed to the enhanced osteogenesis. Interestingly, we 
found the LUM gene upregulated 12.6-fold over control cells. Its roles in collagen 
formation, epithelial cell migration, and tissue repair suggest a possible role for 
TRPM4 on bone development [44, 45]. 
When TRPM4 knockdown cells were placed in adipogenic medium, they 
failed to differentiate into adipocytes. Of the genes related to this process, the TRB3 
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was downregulated 24.7-fold compared to control cells. This finding is consistent 
with reports in type 2 diabetic rats, where silencing of the TRB3 decreases 
adipocyte formation [46]. Two other notable genes, SFRP1 and MMP3, were 
upregulated in both groups. TRPM4 knockdown inhibited SFRP1 expression 10.8-
fold compared to control cells, and SFRP1 is reported to be a regulator of the 
Wnt/β-catenin pathway. Its expression enhances adipocyte differentiation in 
humans and mice [47]. The analysis also revealed a 22.9-fold increase in MMP3 
expression compared to control cells. The knockout of this gene also enhances 
adipogenesis during mammary gland involution in mice, along with adipocyte 
hypertrophy [48]. The effects of TRPM4 knockdown on the TRB3, SFRP1, and 
MMP3 genes are expected to inhibit adipocyte differentiation based on their roles 
during adipogenesis.  
Conclusion 
TRPM4 is a CAN channel present in DFSCs. These stem cells not only 
express the TRPM4 gene but also have currents typical for the channel. Functional 
experiments suggested that TRPM4 acts as an inhibitor of osteogenesis, since 
channel suppression increased mineralization and ALP enzyme activity. However, 
it appears to be required and/or facilitates adipogenesis due to the absence of 
adipocyte differentiation in TRPM4 knockdown cells. The effect of TRPM4 on 
osteogenesis and adipogenesis seems to be linked to the Ca2+ signals, which could 
be a key factor controlling expression of certain genes. 
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CHAPTER 3: HISTAMINE-INDUCED Ca2+ SIGNALLING IS 
MEDIATED BY TRPM4 CHANNELS IN HUMAN ADIPOSE- 
DERIVED STEM CELLS* 
 
3.1 INTRODUCTION  
Transient receptor potential channels (TRPs) are a family of proteins 
originally identified in the Drosophila melanogaster visual system and have 
important roles in cellular function. All TRPs include six transmembrane segments 
with the pore region between segments 5 and 6 and intracellular N- and C-termini. 
They are divided into the following six subfamilies: TRPC (canonical), TRPV 
(vanilloid), TRPM (melastatin), TRPP (polycystin), TRPML (mucolipin) and 
TRPA (ankyrin) [1]. TRPM4 belongs to the melastatin subfamily, and TRPM4 and 
TRPM5 are the only Ca2+-activated channels [2, 3]. Although not permeable to 
Ca2+, TRPM4 is proposed to facilitate voltage-dependent Ca2+ channel (VDCC) 
activation in excitable cells and to decrease the driving force for Ca2+ influx via 
store-operated Ca2+ channels (SOCs) in non-excitable cells by depolarization [2, 4, 
5]. Recently, we have reported that molecular inhibition of TRPM4 inhibits 
adipogenesis in rat dental follicle stem cells (rDFSCs), which suggests that the 
channel is required for adipocyte differentiation [6]. This regulatory mechanism is 
mediated via Ca2+ signalling and the expression of specific adipogenic genes. In 
rDFSCs, inhibition of TRPM4 transforms the primary and secondary phases of the 
Ca2+ signals into a gradual and sustained increase that is similar to the one observed  
 
* This research was originally published in Biochemical Journal. Authors: Tran 
Doan Ngoc Tran, Olga Zolochevska, Marxa L. Figueiredo, Hai Wang, Li-Jun Yang, 
Jeffrey M. Gimble, Shaomian Yao and Henrique Cheng. Histamine-induced 
Ca2+ signalling is mediated by TRPM4 channels in human adipose-derived stem 
cells. Biochemical Journal. 2014; 463: 123-134 © the Biochemical Society. 
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in non-excitable cells (e.g. immune cells) that utilizes SOCs as the main pathway 
for Ca2+ influx [7, 8]. The opposite phenomenon occurs in excitable cells (e.g. 
pancreatic α- and β-cells and dendrite), where TRPM4 suppression decreases the 
magnitude of the Ca2+ signals due to a reduction in VDCC channel activity [5, 9, 
10]. 
Ionized Ca2+ is a well-known second messenger controlling basically every 
cellular process. Elevations in [Ca2+]i are observed frequently in response to 
hormone and growth factor stimulation as well as spontaneous increases. These 
Ca2+ signals are often due to influx from the extracellular space and release from 
intracellular stores. In stem cells, SOCs were first reported by Kawano et al. [53]. 
It was shown that Ca2+ influx contributes to the signals that co-ordinate cell 
proliferation and differentiation. In addition, Ca2+ oscillations are important for 
specificity and effectiveness of gene expression, for example nuclear factor of 
activated T-cells (NFAT) transcription activity [11]. This is supported by the fact 
that NFAT translocation into the nucleus is needed for stem cell differentiation, but 
halts at the terminal stages of adipogenesis and osteogenesis [12, 13]. An increase 
in Ca2+ influx in mesenchymal stem cells accelerates osteogenic differentiation via 
the mitogen-activated protein kinase (MAPK) pathway [13]. Ca2+ signalling is also 
required for embryonic and mesenchymal stem cell cycle progression through 
G1/S-phase by inducing expression of c-myc, a key gene for self-renewal and 
pluripotency [14–16]. Furthermore, increases in [Ca2+]i up-regulate peroxisome-
proliferator-activated receptor γ (PPARγ) gene expression, a critical transcription 
factor for adipocyte differentiation [17]. 
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Ion channels are important regulators of cell proliferation and 
differentiation due to their ability to conduct Ca2+ directly into cells or indirectly by 
controlling the opening and closure of Ca2+ channels. In the first report of TRPM4 
in stem cells, we have determined that the channel is required for adipocyte 
differentiation in rDFSCs by controlling Ca2+ signals and adipocyte-specific genes 
[6]. There are no reports of TRPM4 in any other type of stem cell. However, 
members of the TRP family such as the TRPM7 are required for bone marrow stem 
cell proliferation and viability [18]. The channel is also important for early 
embryonic development [19]. TRPM2 enhances mesenchymal stem cell 
proliferation [20]. Among non-TRPs, the delayed rectifier K+ and Ca2+-activated 
K+ channels are required for mesenchymal stem cell proliferation [21–23]. In 
human adipose-derived stem cells (hASCs), the delayed rectifier K+, Ca2+-activated 
K+, transient outward K+ and tetrodotoxin (TTX)-sensitive transient inward 
Na+ channels are present, although their roles in differentiation remain unknown 
[24]. Despite the lack of information on TRPs during hASC differentiation, some 
control the functioning of pre-adipocyte and adipocyte cells. TRPC1 and TRPC5 
are responsible for constitutive Ca2+ influx in differentiated 3T3-L1 cells and 
adipose tissues [25]. Expression of TRPV1 diminishes during adipogenesis in 
obese humans and mice [26], and channel activation results in Ca2+ influx and 
uncoupling of protein 1-dependent thermogenesis [27]. Nevertheless, TRPV1-null 
mice fail to become obese on a high-fat diet because of increased thermogenic 
activity [28]. Recently, TRPM8 was shown to stimulate uncoupling protein 1-
dependent thermogenesis and prevent obesity in mice [29]. Because of TRPM4's 
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ability to control Ca2+ signalling in other cell types and its requirement for 
adipogenesis in rDFSCs, we have examined its impact on Ca2+ signals and 
adipocyte differentiation in hASCs, which is a more suitable stem cell type for 
adipogenic studies [30]. 
3.2 MATERIALS AND METHODS 
3.2.1 Reagents 
 All reagents were purchased from Sigma–Aldrich, except for fura 2 
acetoxymethyl ester (fura 2/AM), which was from Molecular Probes, and D-
calcium pantothenate, which was from Acros Organics. 
3.2.2 Cell culture 
 hASCs were isolated from lipoaspirates of abdomen and breast adipose 
tissues according to [31]. The multi-potency of this stem cell type has been 
confirmed by different laboratories [32–36]. Tissues were donated by one 
consenting Caucasian female and one consenting Caucasian male, aged 34 and 
55 years respectively, body mass index (BMI) from 28.2 to 33.78, under a protocol 
reviewed and approved by the Pennington Biomedical Institutional Review Board 
(#PBRC23040) and maintained in Dulbecco's modified Eagle's medium 
(DMEM)/Ham's F-12 medium with 10% FBS (Atlanta Biologicals) and aerated 
with 5% CO2 at 37°C. All experiments were performed with cells from passages 3 
to 8. 
3.2.3 Induction and detection of adipogenesis 
Cells reaching between 80% and 90% confluence were induced with 
differentiation medium containing DMEM/Ham's F-12 supplemented with 3% 
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FBS, 0.25 mM 3-isobutyl-1-methylxanthine (IBMX), 33 μM biotin, 17 μM D-
calcium pantothenate and 100 nM human insulin for 3 days. Adipocyte medium 
having the same composition as differentiation medium except for IBMX and 
rosiglitazone (5 μM) was changed every 3 days from day 3 to day 21 [37]. 
Adipogenesis was determined by Oil Red O staining. Briefly, cells were washed 
with PBS, fixed with 10% formalin for 10 min, washed twice with distilled water 
and incubated with 60% propan-2-ol for 5 min. Cells were then stained with Oil 
Red O solution for 5 min and washed again to remove excess dye. The presence of 
lipid droplets was visualized by phase-contrast microscopy using an inverted 
microscope (Zeiss). Adipocyte cell count was performed with Image-Pro® Analyzer 
7.0 (Media Cybernetics). 
3.2.4 RT-PCR 
Total RNA was extracted from hASCs using the RNAqueous-4PCR® kit 
according to the manufacturer's instructions (Ambion). The RNA was purified 
using DNase I treatment. Reverse transcription (RT) and PCR were performed 
using the RETROscript® kit (Ambion). Total RNA was extracted from abdominal 
adipose tissue from three females, ages 40–60 years, BMI from 27 to 30, according 
to an approved protocol by Institutional Review Board of the University of Florida 
using TRIzol® reagent (Invitrogen). Briefly, 300 mg of human adipose tissue was 
placed in a mortar pre-chilled with liquid nitrogen. A pestle was used to 
homogenize the deep frozen tissue with the presence of liquid nitrogen throughout 
the process. To the sample, 1 ml of TRIzol® was added, and the mixture was 
transferred to a 1.5 ml Eppendorf tube. After 5 min of incubation at room 
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temperature, 100 μl of chloroform was added to the mixture, vortex-mixed 
vigorously for 15 s and kept at room temperature for another 10 min. The mixture 
was phase-separated by centrifugation at 12000 g for 15 min at 4°C. Following 
centrifugation, the mixture was kept at 4°C for 30 min to let the fat solidify. After 
careful removal of the upper layer of fat, the middle aqueous phase was transferred 
into a new tube. To precipitate the RNA, 500 μl of propan-2-ol was added. After 
10 min of incubation at room temperature, precipitated RNA was pelleted by 
centrifugation at 12000 g for 10 min at 4°C. The pellet was then washed with 75% 
ethanol. After briefly air-drying the RNA pellet, 50 μl of RNase-free water was 
added to dissolve the RNA and the concentration was determined by measuring 
the A260/A280 ratio. Transcriptor first- strand cDNA synthesis kit was purchased 
from Roche. Random primer and 4 μg of total RNA were used to generate cDNA. 
The primers used are listed in Table 3.1. 
Table 3.1 List of primers of ion channel genes for RT-PCR 
 
Gene Forward primer  
(5’-3’) 
Reverse primer  
(5’-3’) 
Size 
(bp) 
TRPM4  
(for hASCs) 
AGCATGGTGCCGGAG
AA 
GGTGTCTCTATTCCGG
ACCACA 
600 
TRPM4  
(for human 
adipose 
tissue) 
CCTCTTTGGCGAGTGC
TATC 
CAAAAGAAGGCGAGA
ACCAG 
222 
TRPM5 CAGAACATCACCTCA
CACCAG 
GGTTCTCGCTCTTCTG
GTTC 
640 
TRPM6 CCAGAGCCAGGAGAA
AACAG 
AAAGGGGAACTCTCC
TCCAA 
419 
TRPM7 TGAAACGAGTGAGTT
CTCTTGCTG 
CACAGGTGTAAATGG
AATGCTC 
309 
Cav1.1 AACGCCAAGAGGAGT
ATTATG 
ATGGCTGTTGCTATG
GTTGC 
425 
Cav1.2 CTGGACAAGAACCAG
CGACAGTGCG 
ATCACGATCAGGAGG
GCCACATAGGG 
562 
75 
 
(Table 3.1 continued) 
GAPDH, glyceraldehyde-3-phosphate dehydrogenase. 
 
3.2.5 Quantitative RT–PCR 
From each sample, 2 μg of total RNA was reverse-transcribed into 20 μl of 
cDNA. Each PCR was prepared by mixing 2 μl of the cDNA with 2× SYBR Green 
PCR master mix (Life Technologies) and gene-specific primers (Table 3.2). The 
PCR was carried out with ABI 7300 real-time PCR system (Life Technologies) to 
obtain the CT value. Relative gene expression (RGE) was calculated by the 
ΔCT method using β-actin as the endogenous control for normalization and 
Cyclophilin B as the reference control with an RGE of 1.  
Table 3.2 List of primers of adipogenic marker genes for quantitative RT-PCR 
 
 
Gene Forward primer  
(5’-3’) 
Reverse primer  
(5’-3’) 
Size 
(bp) 
Cav1.3 TATGTGGCCCTCCTCA
TAGC 
CTCAGGGTCACAGAG
CTTCC 
219 
Cav1.4 GGACCATGGCCCCAT
CTATAATTACCG 
CCTGAAGAGCCACCT
TGCCGAAC 
764 
GAPDH AACAGCGACACCCAC
TCCTC 
GGAGGGGAGATTCAG
TGTGGT 
258 
Gene Forward primer  
(5’-3’) 
Reverse primer  
(5’-3’) 
Size 
(bp) 
C/EBPα CGGTGGACAAGAACA
GCAAC 
CGGAATCTCCTAGTC
CTGGC 
365 
C/EBPβ 
 
CACAGCGACGACTGC
AAGATCC  
CTTGAACAAGTTCCG
CAGGGTG 
188 
PPARγ2 GCTGTTATGGGTGAA
ACTCTG 
ATAAGGTGGAGATGC
AGGTTC 
325 
 
aP2  TGGTTGATTTTCCATC
CCAT  
TACTGGGCCAGGAAT
TTGAT 
150  
 
Adiponectin GGCCGTGATGGCAGA
GAT 
TTTCACCGATGTCTCC
CTTAGG 
88 
Cyclophilin 
B 
GGAGATGGCACAGGA
GGAAA 
CGTAGTGCTTCAGTTT
GAAGTTCTCA 
72 
76 
 
3.2.6 Western blot analysis 
hASCs from two different lines were grown to confluency and collected 
into protein lysis buffer with the addition of protease inhibitor cocktail. Protein 
concentration was determined by the Bradford method. BSA protein standard was 
purchased from Bio-Rad Laboratories. Then, 50 μg of protein was separated by 
SDS/8% PAGE. Proteins were transferred on to a nitrocellulose membrane and 
subjected to sequential Western blotting analysis with anti-TRPM4 (1:300) 
antibody (Alomone Labs) overnight at 4°C and visualized by ECL Prime Western 
Blotting Detection Reagent (GE Healthcare Life Sciences) followed by anti-Cav1.2 
(1:300) antibody (Alomone Labs) without stripping off the membrane. 
3.2.7 Generation of stable TRPM4 knockdown cells 
hASCs were transduced with lentivirus plasmids (Sigma–Aldrich) in a 
pLKO.1 backbone containing either non-specific control (SHC002) or shRNAs 
specific for human TRPM4 (TRCN0000044924 and TRCN0000044926) under the 
control of the U6 promoter, with the puromycin-resistance gene and a GFP gene. 
Cells were selected in puromycin and used for electrophysiology, Ca2+ imaging 
analysis and adipogenic differentiation experiments. 
3.2.8 Electrophysiology 
Cells were maintained in standard modified Ringer's solution of the 
following composition: 140 mM NaCl, 2.8 mM KCl, 1 mM CaCl2, 2 mM MgCl2, 
4 mM glucose and 10 mM Hepes/NaOH (pH 7.2). Replacement of extracellular 
Na+ was accomplished by 140 mM N-methyl-D-glucamine (NMDG). The internal 
solution contained 120 mM caesium glutamate, 8 mM NaCl, 1 mM MgCl2, 10 mM 
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caesium 1,2-bis-(o-aminophenoxy) ethane-N,N,N',N'-tetra-acetic acid (BAPTA), 
10 mM Hepes/CsOH (pH 7.2). The internal solution's buffered Ca2+ concentration 
was adjusted as necessary with CaCl2. The osmolarity of the solutions was ~300 
mOsm/l. TRPM4 currents were recorded in the tight-seal whole-cell configuration 
mode at 21–25°C. High-resolution current recordings were acquired by a computer-
based patch-clamp amplifier system (EPC-10, HEKA). Patch pipettes had 
resistances between 4 and 7 mΩ and were coated with Sigmacote silicon solution 
(Sigma–Aldrich). Immediately following establishment of the whole-cell 
configuration, voltage ramps of 50-ms duration spanning the voltage range of −100 
to +100 mV were delivered from a holding potential of 0 mV at a rate of 0.5 Hz 
over a period of 300 s. All voltages were corrected for a liquid junction potential of 
10 mV between external and internal solutions and calculated using Igor PPT 
Liquid Junction Potential software (Wavemetrics). 
3.2.9 Calcium imaging analysis 
Cells were loaded with 2 μM fura 2/AM for 30 min at 37°C. The imaging 
buffer containing 136 mM NaCl, 4.8 mM KCl, 1.2 mM CaCl2, 1.2 mM MgSO4, 
10 mM Hepes, 4 mM glucose and 0.1% BSA (pH 7.3) was used for fura 2/AM 
loading and perfusion throughout the experiments. Calcium measurements were 
obtained using a dual-excitation fluorimetric imaging system (TILL-Photonics) 
controlled by TILLvisION software. Fura 2/AM loaded cells in a perfusion 
chamber were excited at 340- and 380-nm wavelengths. Fluorescence emissions 
were sampled at a frequency of 1 Hz and computed into relative ratio units of the 
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fluorescence intensity of the difference of wavelengths (F340/F380). Data were 
expressed as averages from several cells from three separate experiments. 
3.2.10 Data analysis 
Patch-clamp recordings, peak Ca2+ signals and adipocyte counts are shown 
as means±S.E.M. and were analysed using a two-tailed and unpaired Student's t test 
(GraphPad Software). Statistical significance was established at P<0.05. 
3.3 RESULTS  
3.3.1 TRPM4 expression in hASCs and human adipose tissue  
Using RT–PCR, we have detected TRPM4 transcripts in hASCs and human 
adipose tissue, but not TRPM5, a related channel with similar function. In addition, 
we have identified TRPM6 and TRPM7 gene expression in stem cells and 
differentiated adipocytes (Figure 3.1,A). The presence of TRPM4 protein in hASCs 
was confirmed in two different cell lines by Western blot analysis (Figure 3.1,B). 
3.3.2 Biophysical characterization of TRPM4 in hASCs 
Since hASCs expressed the TRPM4 gene, we have performed patch-clamp 
recordings in the whole-cell configuration mode to determine whether the channel 
was functionally active. On the basis of the Ca2+-activated property of TRPM4, we 
have perfused a single hASC with intracellular buffered Ca2+ concentration ranging 
from 0.1 to 3 μM. As a result, currents with the characteristics of those previously 
described [2, 7] developed in a concentration-dependent manner with peak 
amplitude at 3 μM (Figures 3.1,C and 3.1,D). The current–voltage (I–V) 
relationship taken from representative cells at 300 s into the recording for each Ca2+  
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concentration is shown in Figure 3.1,E. The calculated EC50 was 0.9 μM and the 
Hill coefficient was 9.09 (Figure 3.1,F). Another property of TRPM4 is the voltage- 
 
Figure 3.1 TRPM4 expression and functionality in hASCs. (A) Expression of the 
TRPM4 gene in hASCs and human adipose tissue. In addition, we have detected 
the presence of TRPM6 and TRPM7. RT–PCR was performed with specific 
TRPM4, TRPM5, TRPM6 and TRPM7 primers. Distilled water and 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) served as negative and 
positive controls respectively. (B) Western blot analysis confirmed the presence of 
TRPM4 protein in two different hASC lines. (C) Increases in the intracellular Ca2+ 
activated TRPM4 currents in a concentration-dependent manner. Average inward 
and outward currents during perfusion of single cells with increasing intracellular 
buffered Ca2+ concentrations. Traces represent the means±S.E.M. (n=5–10 cells per 
concentration) extracted at −80 mV and +80 mV from a holding potential of 0 mV. 
(D) Average peak inward currents from cells represented in (C). (E) I–V 
relationship under experimental conditions described in (C) taken from 
representative cells at 300 s into the recordings. (F) The calculated EC50 value and 
Hill coefficient for different Ca2+ concentrations. 
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dependency, where positive potentials increase its open probability and negative 
potentials decreases it [2]. Hence, we have performed patch-clamp recordings with 
holding potentials from −80 mV to +60 mV while perfusing cells with 1 μM 
intracellular buffered Ca2+ concentration. Under these conditions, we have obtained 
the greatest current amplitude at +60 mV and the smallest at −80 mV (Figure 
3.2,A). The I–V relationship obtained from representative cells at 300 s is shown 
in Figure 3.2,B. To investigate TRPM4's ionic conductivity, we have replaced NaCl 
in the extracellular solution with an equimolar concentration of NMDG and 
performed recordings with 1 μM intracellular buffered Ca2+ concentration at +60 
mV holding potential, which gave the maximum current amplitude. Replacement 
of Na+ from the extracellular solution abolished TRPM4 currents compared with 
cells maintained under Na+ containing buffer, even under high Ca2+ and positive 
holding potential conditions (Figure 3.2,C). The I–V relationship confirmed the 
lack of channel activity in the absence of Na+ (Figure 3.2,D). 
3.3.3 Inhibition of TRPM4 activity by 9-phenanthrol 
Next, we have performed patch-clamp recordings using the specific TRPM4 
blocker 9-phenanthrol [38–40] to further confirm its presence in hASCs. Pre-
treatment of cells with 0.3–10 nM 9-phenanthrol inhibited TRPM4 currents in a 
concentration-dependent manner during perfusion with 1 μM intracellular buffered 
Ca2+ concentration and 0 mV holding potential (Figures 3.3,A and 3.3,B). The I– 
V relationship showed the reduction in TRPM4 activity with increased 9-
phenanthrol concentration (Figure 3.3,C). The calculated IC50 and Hill coefficient 
in hASCs were 1.75 nM and 1.61 respectively (Figure 3.3,D). 
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Figure 3.2 Voltage-dependency and ionic conductivity of TRPM4. (A) Average 
inward and outward currents under −80 mV, 0 mV and +60 mV holding potentials 
during perfusion of cells with 1 μM intracellular buffered Ca2+ concentration. 
Traces are means±S.E.M. (n=3–8 cells per holding potential). (B) I–V relationship 
under experimental conditions described in (A) obtained from representative cells 
at 300 s. (C) Replacement of NaCl by NMDG in the extracellular buffer solution 
inhibited TRPM4 currents. Average inward and outward currents from hASCs 
maintained in control NaCl solution compared with NMDG solution during 
perfusion with 1 μM intracellular buffered Ca2+ concentration at +60 mV holding 
potential. Traces are means±S.E.M. (n=3–8 cells per condition). (D) I–
V relationship under experimental conditions described in (C) taken from 
representative cells at 300 s. 
3.3.4 Molecular suppression of TRPM4 inhibits channel activity 
To determine the importance of TRPM4 for adipogenesis and 
Ca2+ signalling, we have generated stable knockdown cells using shRNA and a 
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Figure 3.3 Pharmacological suppression of TRPM4 by 9-phenanthrol. (A) Pre-
treatment of cells with the specific TRPM4 blocker 9-phenanthrol inhibited channel 
currents in a concentration-dependent manner during perfusion of cells with 1 μM 
buffered Ca2+ concentration and 0 mV holding potential. (B) Average peak inward 
currents from cells represented in (A) and compared with control cells without 
blocker. (C) I–V relationship under experimental condition described in (A) 
obtained from representative cells at 300 s. (D) Calculated IC50 and Hill coefficient 
for different 9-phenanthrol concentrations. Traces represent means±S.E.M. (n=6–
18 cells per concentration). 
 
lentiviral vector as a delivery agent. The goal of this approach is to obtain cells with 
reduced TRPM4 activity, which is confirmed by the current amplitude during 
electrophysiological recordings. We have compared TRPM4 currents between 
control cells transduced with a scramble sequence shRNA and specific TRPM4 
shRNA cells during perfusion with 1 μM intracellular buffered Ca2+ concentration 
at +60 mV holding potential. The currents under these conditions were reduced 
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significantly with TRPM4 knockdown (Figures 3.4,A and 3.4,B). This confirmed 
the inhibitory effect of shRNA on channel activity.  
3.3.5 TRPM4 suppression decreases lipid droplet accumulation and adipocyte 
gene expression during adipogenesis 
 
Lipid droplet accumulation is a well-accepted marker for adipocyte 
differentiation [41]. Hence, we have performed a differentiation assay using Oil 
Red O staining to determine whether there were differences between control 
shRNA and TRPM4 knockdown cells after 21 days in adipogenic medium. In 
accordance with our previous findings in rDFSCs, molecular suppression of 
TRPM4 significantly reduced lipid droplet accumulation over a 21-day period of 
differentiation (Figure 3.4,C). In addition, TRPM4 knockdown with two different 
sets of shRNAs decreased the expression of CCAAT/enhancer-binding protein α 
(C/EBPα), C/EBPβ, PPARγ2, adipocyte fatty acid-binding protein (aP2) and 
adiponectin, which are adipocyte marker genes (Figure 3.4,D). 
3.3.6 TRPM4 affects Ca2+ signalling in response to histamine stimulation 
An increase in intracellular Ca2+ signals is often seen during stem cell 
differentiation and is important for this process. Therefore, we have tested whether 
inhibition of TRPM4 activity in hASCs affected Ca2+ signals upon agonist 
stimulation. We have selected histamine due to its ability to increase intracellular 
Ca2+ and stimulate differentiation of stem cells [42–44]. Stimulation of control wild 
type cells with 1–300 μM histamine resulted in a concentration-dependent increase 
in the [Ca2+]i with maximum responses at 300 μM (Figures 3.5,A and 3.5,B). Next, 
we examined the histamine receptor mediating the increases using the 300 μM.  Pre- 
treatment of wild-type cells with 10 μM chlorpheniramine, a histamine receptor 1 
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Figure 3.4 TRPM4 knockdown by shRNA inhibits adipocyte differentiation. (A) 
Inhibition of TRPM4 activity was confirmed by the decrease in the current 
amplitude under 1 μM intracellular buffered Ca2+ concentration and +60 mV 
holding potential and compared with control shRNA cells. (B) I–V relationship 
under experimental conditions described in (A) obtained from representative cells 
at 300 s. Traces represent means±S.E.M. [n=5 (control shRNA) and 6 (TRPM4 
shRNA) cells]. (C) Control shRNA and knockdown cells differentiated into 
adipocytes for 21 days and stained with Oil Red O for the presence of lipid droplets 
(×20 magnification). Note the reduction in lipid droplet accumulation with TRPM4 
suppression. (D) Molecular suppression of TRPM4 with two different sets of 
shRNAs decreased adipocyte marker gene expression compared with control cells 
after 14 days in adipocyte differentiation medium. 
 
(H1) receptor antagonist, completely abolished the Ca2+ signals generated by 
histamine, but not 100 μM cimetidine, an H2 antagonist (Figures 3.5,C–3.5,E). 
Because TRPM4 is reported to control Ca2+ signals in both excitable and non- 
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Figure 3.5 Histamine-induced increases in intracellular Ca2+ concentration. (A) 
Average Ca2+ signals during stimulation of hASCs with increasing histamine 
concentrations. (B) Average peak increases for each histamine concentration. (C–
D) The inhibitory effects of chlorpheniramine and cimetidine on histamine-induced 
Ca2+ signals are shown. (E) Average peak increases after treatment of cells with the 
respective receptor blocker and compared with control cells without blocker. 
Values are means±S.E.M.; n=49–272 cells per group from three separate 
experiments; *P< 0.0001. 
 
excitable cells, we have tested whether channel suppression would alter the signals 
generated by histamine. Indeed, TRPM4 knockdown significantly decreased the 
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responses to 300 μM histamine during adipogenic differentiation (Figures 3.6,A–
3.6,D). 
3.3.7 TRPM4-mediated depolarization facilitates the opening of VDCCs 
 Inhibition of TRPM4 activity in hASCs decreased the magnitude of the 
Ca2+ signals compared with control shRNA cells (Figure 3.6). This effect was 
similar to the ones observed in excitable cells of the pancreas [5, 9] that rely on 
depolarization and the opening of VDCCs for Ca2+ influx. Hence, we have 
examined VDCC gene expression in hASCs using RT–PCR analysis. The results 
revealed that the L-type Cav1.2 channel was the main VDCC expressed in this stem 
cell (Figure 3.7,A). We have also detected Cav1.2 protein along with TRPM4 
(Figure 3.7,B). To determine whether it contributed to Ca2+ influx, we have 
performed Ca2+ imaging analysis with nimodipine, an L-type Ca2+ channel blocker 
during histamine stimulation. Pre-treatment with 1–30 μM nimodipine decreased 
the amplitude of the Ca2+ signals compared with control wild-type cells without the 
blocker but did not abolish the signals even at the highest concentration (Figures 
3.7,C–3.7,G). Therefore, we have investigated the additional Ca2+ source and 
confirmed the involvement of TRPM4 in VDCC activation by comparing the 
responses to histamine under extracellular Ca2+-free conditions and after depletion 
of endoplasmic reticulum (ER) Ca2+ with thapsigargin (Figure 3.7,H). Under 
control conditions with CaCl2 in the extracellular buffer and without thapsigargin, 
TRPM4-knockdown decreased the magnitude of the Ca2+ signals compared with 
control shRNA cells. When the extracellular   Ca2+ was removed from the buffer 
solution, both control shRNA and TRPM4-knockdown cells had reduced but  
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Figure 3.6 TRPM4 knockdown decreases the magnitude of the Ca2+ signals by 
histamine during adipogenesis. (A–C) Average Ca2+ signals generated by histamine 
in control shRNA and TRPM4 knockdown cells at days 0, 7 and 14 of 
differentiation. (D) Comparison between the average peak Ca2+ increases from 
control shRNA and TRPM4 knockdown cells at the same time point and compared 
with day 0. Values are means±S.E.M.; n=37–338 cells from three separate 
experiments; *P<0.05 comparing control and knockdown at the same time point; 
#P<0.05 comparing same group with day 0. 
comparable responses. Pre-treatment of cells with thapsigargin almost abolished 
the responses to histamine in both groups. This indicated that the mechanism by 
histamine increased intracellular Ca2+ was initiated by ER release followed by 
influx, and the opening of VDCCs was facilitated by TRPM4. 
3.3.8 Histamine stimulates adipocyte differentiation 
Since histamine stimulates the differentiation of other types of stem cells 
[42–44], we have examined whether it would affect adipogenesis in hASCs.  
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Figure 3.7 hASCs express VDCCs and utilize different Ca2+ sources for histamine 
responses. (A) We have detected Cav1.2 gene expression in wild-type hASCs, an 
L-type VDCC, but not Cav1.1, Cav1.3 or Cav1.4. Distilled water and 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) served as negative and 
positive controls respectively. (B) In addition to TRPM4 protein, we have also 
detected Cav1.2 protein in two different hASC lines using Western blot analysis. 
(C–F) Pre-treatment of wild-type cells with increasing nimodipine concentrations, 
an L-type VDCC blocker, reduced the magnitude of the Ca2+signals in response to 
histamine stimulation but did not abolished them. (G) Average peak Ca2+ increases 
by histamine after VDCC channel blockage with different nimodipine 
concentrations and compared with controls cells without the blocker. (H) 
Comparison between peak Ca2+ signals from control shRNA and TRPM4 
knockdown cells during histamine stimulation under extracellular free 
Ca2+ condition and after depletion of intracellular Ca2+ stores with thapsigargin. 
Values are means±S.E.M.; n=132–338 cells from three separate experiments; 
*P<0.001 comparing control shRNA and TRPM4 shRNA cells under same 
experimental condition. 
Histamine (200 nM) supplementation to the adipogenic medium significantly 
increased lipid droplet accumulation and the number of adipocytes after 14 days of 
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differentiation compared with control medium without histamine (Figures 3.8,A–
3.8,C). These results confirmed its stimulatory effect on the differentiation process. 
3.4 DISCUSSION 
In a recent report, we have described the presence of TRPM4 in rDFSCs 
and demonstrated that the channel is required for adipogenesis [6]. Since hASCs 
are the normal precursors for adipocytes, we have investigated TRPM4 in this 
type of stem cell. We have identified TRPM4 gene expression and protein in hASCs 
and human adipose tissue. We have also ruled out the possibility of TRPM5 
affecting differentiation and functioning of these cells since hASCs and adipocytes 
did not express this particular channel. Our findings that adipose tissue expresses 
TRPM4 suggest a potential role in adipocytes. In fact, white and brown adipocytes 
have Ca2+-activated non-selective cation (CAN) channels with similar 
characteristics of TRPM4, such as Ca2+-dependent activation, conductivity, 
reversal potential and voltage-dependency [45–47]. However, none of these CANs 
have been recognized until now and it is possible that some might be TRPM4. 
Furthermore, perfusion of hASCs with increasing buffered Ca2+concentrations 
activated TRPM4 in a concentration-dependent manner. The calculated EC50 value 
and Hill coefficient of 0.9 μM and 9.09 are very similar to the ones in rDFSCs. 
Additional characterization of TRPM4 in other stem cells is needed to determine 
whether there are differences in biophysical properties. In hASCs, we have 
confirmed TRPM4's voltage-dependency, where negative holding potential 
inhibited and positive holding potential facilitated channel activity [5, 9]. The 
channel also conducted Na+ as the main ion since its replacement by NMDG  
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Figure 3.8 Histamine stimulates adipogenesis in hASCs. Wild-type cells were 
differentiated into adipocytes for 14 days with and without 200 nM histamine in 
the adipogenic medium and stained with Oil Red O for the presence of lipid droplets 
(×20 magnification). Note the increase in lipid droplet accumulation with histamine 
supplementation. (A) Brightfield. (B) Oil Red O staining. (C) Average adipocytes 
counted from a total of 18 frames taken at ×10 magnification. Values are 
means±S.E.M.; n=667 (− histamine) and 991 (+ histamine) cells; *P<0.0001. 
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resulted in complete current suppression. The specific blocker 9-phenanthrol 
inhibited TRPM4 activity in a concentration-dependent manner. These results 
showed that the channel is not only is expressed in hASCs but also is functionally 
active. 
To investigate TRPM4's impact on adipogenesis, we have generated stable 
knockdown cells with the use of shRNA. This approach significantly reduced 
channel activity as confirmed by patch-clamp recordings. When TRPM4-
knockdown cells were cultured in adipogenic medium, there was decreased lipid 
droplet accumulation and expression of adipocyte marker genes. As with rDFSCs, 
this is evidence that adipogenesis in hASCs is dependent on functional TRPM4 
channels. This process may require TRPM4 activity alone or in combination with 
other proteins. Heteromultimerization of TRPM4 with sulfonylurea receptor 1 
(SUR1) increases channel sensitivity to intracellular Ca2+ and affinity to calmodulin 
[48]. These Ca2+ signals are reported to activate transcription factors and enzymes 
involved in adipogenesis [e.g. PPARγ and fatty acid synthase (FAS)] and to 
suppress adipolysis [49–51]. Other TRPM family members such as TRPM7 are 
important for proliferation and conversion of pre-adipocyte cells into the mature 
adipocyte [52]. Using RT–PCR, we have identified TRPM6 and TRPM7 gene 
expressions in hASCs and human adipose tissue; however, their roles remain to be 
determined. 
One of the goals of the present study was to provide insight into the 
Ca2+ signalling mechanism controlling adipogenesis in hASCs. Using histamine, a 
well-known activator of Ca2+ signals and regulator of stem cell differentiation, we 
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have found that TRPM4 suppression reduced the magnitude of the signals 
compared with control shRNA cells. This was an unexpected finding since TRPM4 
knockdown in rDFSCs enhances Ca2+ signalling. From this observation, we have 
reasoned that hASCs use VDCCs as their main pathway for Ca2+ influx (excitable 
cells) instead of SOCs (non-excitable cells) [53]. This is supported by findings in 
pancreatic α- and β-cells, where TRPM4 suppression decreases the magnitude of 
Ca2+ signals generated by agonist stimulation [5, 9]. In non-excitable cells, the 
opposite occurs when TRPM4 is inhibited because depolarization decreases the 
driving force for Ca2+ entry via SOCs [6, 7, 54]. In support of our excitable cell 
hypothesis, we have found that hASCs expressed the Cav1.2 channel, a main type of 
VDCC. Furthermore, the VDCC blocker (nimodipine) decreased the magnitude of 
the Ca2+signals generated by histamine. These findings suggested that Ca2+ influx 
via the Cav1.2 channel is a component of the Ca
2+ signals. Experiments under 
extracellular Ca2+-free conditions and after depletion of the intracellular Ca2+stores 
were performed to examine additional Ca2+ sources. From our data, it was clear that 
TRPM4 is required for the full histamine response since channel knockdown 
reduced the magnitude of the Ca2+ signals. Experiments in the absence of 
extracellular Ca2+ had a similar effect to TRPM4 knockdown. This can be explained 
by the fact that TRPM4 depolarization opens VDCCs resulting in Ca2+ influx. 
Without Ca2+ in the extracellular buffer or TRPM4 activity there is no influx. When 
the intracellular Ca2+ stores were depleted using thapsigargin, the Ca2+ signals were 
abolished regardless of whether or not TRPM4 was suppressed. These Ca2+ signals 
generated by histamine in hASCs are typical of Gq-coupled receptors that increase 
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inositol 1,4,5-trisphosphate (IP3) formation and mobilize intracellular Ca
2+ from the 
ER. This initial Ca2+ release is likely to activate TRPM4, which depolarizes the cell 
leading to the opening of VDCCs to further increase the magnitude of the 
Ca2+ signals and stimulate PPARγ and FAS during adipogenesis according to the 
proposed mechanism shown in Figure 3.9. This would explain in part why TRPM4 
knockdown inhibited adipogenesis in hASCs. Despite the differences in the 
Ca2+ signalling pattern between rDFSCs and hASCs, both showed decreased lipid 
droplet accumulation and expression of adipocyte marker genes with channel 
knockdown. This raises the possibility that other factors that are not Ca2+-dependent 
but are linked to TRPM4 may control adipogenesis.  
Another interesting finding was the presence of two histamine receptors (H1 
and H2) in hASCs as determined using chlorpheniramine and cimetidine. From our 
results, H1 receptors seem to be the most predominant since chlorpheniramine 
completely inhibited the Ca2+ signals, whereas cimetidine reduced the responses by 
50%. Both receptors, especially H1, are critical for differentiation. For example, 
H1 receptors are up-regulated during 3T3-L1 fibroblast differentiation and 
antagonists or receptor knockdown inhibits insulin-induced adipogenesis [51]. 
Histamine increases dendritic cell differentiation via H1 and H2 receptors 
becausereceptor blockage reduces the expression of differentiation markers [42]. In 
another study, H1 is the most important for monocyte differentiation despite the 
expression of H2 [55]. Histamine also increases the expression of receptor activator 
of nuclear factor κB ligand during osteoclastogenesis via H1 receptors [56]. Both 
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receptor types are critical for histamine-induced neural stem cell proliferation and 
differentiation [44]. 
 
Figure 3.9 Proposed mechanism for histamine and TRPM4 control of 
Ca2+ signalling and adipogenesis in hASCs. Activation of histamine receptors, 
mainly the H1 type, increases intracellular Ca2+ via Gq-proteins and the 
phospholipase C (PLC)/IP3 pathway. The initial Ca
2+ release from the ER activates 
TRPM4, which depolarizes cells leading to the opening of VDCCs and Ca2+ influx. 
The Ca2+ release and influx are the sources for the Ca2+ signals that could control 
the activation of transcription factors and enzymes involved in adipogenesis. 
In addition to H1/H2, the H4 receptor is described in bone marrow mesenchymal 
stem cells; however, only H1 mediates the Ca2+ signals [57]. Based on our findings 
and reports by other laboratories, we have found that the increases in intracellular 
Ca2+ mainly via H1 receptors are essential for adipocyte differentiation and/or 
function. 
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Conclusions 
We have characterized for the first time TRPM4 in hASCs and 
demonstrated its importance for histamine-induced Ca2+ signalling and 
adipogenesis. The mechanism appears to involve in part Ca2+ release from the ER 
and influx via VDCCs with TRPM4 providing the depolarization necessary to 
activate the channel. The excitable cell characteristic of hASCs was a surprising 
finding since most undifferentiated stem cells are known to be of the non-excitable 
type. 
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CHAPTER 4: ARGININE VASOPRESSIN INHIBITS 
ADIPOGENESIS IN HUMAN ADIPOSE-DERIVED STEM 
CELLS* 
 
4.1 INTRODUCTION 
 Arginine vasopressin (AVP) is synthesized in the paraventricular and 
supraoptic nucleus of the hypothalamus and is secreted from the posterior pituitary 
gland mainly in response to dehydration. It is also detected in ovaries, adrenal 
gland, testis, thymus and pancreas [1-5]. AVP mediates its effects via three G 
protein-coupled receptors, the V1a, V1b, and V2. The V1a receptor can be found 
in lymphocytes, smooth muscle and mesangial cells [6-8]. The V1b receptor is 
present in pancreatic α and β cells, astrocytes and adrenal medulla [9-12]. In 
addition, AVP binds to V2 receptors in the renal distal tubule and collecting duct 
cells to promote water reabsorption during dehydration by activating the cAMP 
pathway [13]. Important physiological roles for AVP include platelet aggregation, 
liver glycogenolysis, uterine motility, vasoconstriction, cell proliferation and 
growth. It stimulates protein synthesis via V1a receptors and insulin, glucagon, 
catecholamine, ACTH secretion via V1b receptors [14]. Activation of V1 receptors 
has a significant impact on intracellular Ca2+ signals because they are coupled to 
Gq-proteins and the phospholipase C-β (PLC-β) and inositol triphosphate (IP3) 
pathway. Increases in IP3 result in Ca
2+ release from the endoplasmic reticulum 
(ER) and influx from the extracellular space [15]. Calcium oscillations are required 
for cell proliferation and differentiation, because it activates transcription factors,  
 
* Reprinted with permission from Elsevier Ltd. Authors: Tran Doan Ngoc Tran, 
Shaomian Yao, Walter H. Hsu, Jeffrey M. Gimble, Bruce A. Bunnell and Henrique 
Cheng. Molecular and Cellular Endocrinology 2015; 406: 1–9. 
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such as nuclear factor of activated T-cells (NFAT) [16]. Translocation of NFAT 
adipogenic and into the nucleus is observed during stem cell differentiation, but 
ends at terminal stages of osteogenic differentiation [17, 18]. Elevation in 
intracellular Ca2+ inhibits adipocyte formation during early stages of differentiation, 
but facilitates it at later stages [19, 20]. An increase in Ca2+ influx activates the 
mitogen-activated protein kinase (MAPK) pathway to stimulate osteogenic 
differentiation in mesenchymal stem cells [18]. Calcium signaling is essential for 
embryonic and mesenchymal stem cell cycle progression via the G1/S phase [21-
23]. They up-regulate peroxisome proliferator-activated receptor γ (PPARγ) gene 
expression, a master transcription factor for adipogenesis. PPARγ increases fatty 
acid synthase activity and triacylglycerol production in lipid droplets [19]. Other 
studies revealed a stimulatory effect of AVP on myoblast and T-cell differentiation 
via V1 receptors [8, 24, 25]. However, AVP inhibits osteoclast differentiation [26]. 
Other physiological functions for AVP include control of thermogenesis by  
increasing UCP-1 protein expression for uncoupling oxidative phosphorylation 
during heat production from brown fat [27]. Studies in V1a receptor knockout mice 
show enhanced lipid metabolism, muscle proteolysis and insulin signaling 
suppression that is supported by observations of impaired glucose tolerance in these 
animals [28]. The anti-lipolytic effect is mediated by Ca2+ signals and the MAPK 
pathway [27, 29]. A reduction in adiponectin mRNA is detected after adipocyte 
stimulation with AVP [27]. This hormone also inhibits ketogenesis by suppressing 
β-oxidation of fatty acid [30]. Pathophysiological conditions such as hypertension 
and obesity are associated with reduced plasma AVP [31, 32]. Obese and sedentary 
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individuals have lower AVP levels compared to lean ones, whereas exercise 
increases hormone secretion [33, 34]. This observation is confirmed in patients 
before and after weight loss [35]. The same study reported an inverse correlation 
between AVP and insulin that is consistent with the knowledge that obese 
nondiabetic individuals have increased insulin and adipose tissue but low AVP 
levels. Patients with multiple symmetric lipomatosis due to alcohol abuse exhibit 
large symmetrical accumulation of non-capsulated fat tissue that is associated with 
reduced AVP secretion caused by alcohol [36]. Interestingly, nicotine stimulates 
AVP secretion and may in part explain why cigarette smokers gain weight after 
they stop smoking [37]. Although Ca2+ signals are reported in hASCs [38], the 
mechanism by which AVP increases intracellular Ca2+ and its role on adipogenesis 
is unknown. In this study, we characterized the AVP receptor subtype, its signaling 
pathway and impact on adipocyte differentiation. 
4.2 MATERIALS AND METHODS 
4.2.1 Reagents 
All reagents were purchased from Sigma Chemical Co. (St. Louis, MO, 
USA), except that fura-2 acetoxymethyl ester (Fura-2AM) was from Anaspec 
(Fremont, CA, USA), d-calcium pantothenate was from Fisher Scientific 
(Pittsburgh, PA, USA), [Arg8] vasopressin (AVP) from American Peptide Co. 
(Sunnyvale, CA, USA) and 2-APB from Cayman Chemical Co. (Ann Arbor, MI, 
USA). 
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4.2.2 Cell culture 
Human adipose-derived stem cells were isolated from lipoaspirates of                                                                      
abdomen, breast adipose tissues, right knee and right scapula donated by consenting 
two Caucasian females and a male, age from 34 to 66 years old, BMI from 23.5 to 
33.78 under a protocol reviewed and approved by the Pennington Biomedical 
Institutional Review Board (#PBRC23040) and maintained in Dulbecco’s modified 
Eagles medium (DMEM)/Ham’s F-12 medium with 10% fetal bovine serum (FBS) 
(Atlanta Biologicals, Lawrenceville, GA, USA) and aerated with 5% CO2 at 37°C. 
All experiments were performed with cells from passages 3-8. 
4.2.3 RT-PCR 
 Total RNA was extracted using the RNAqueous-4PCR® kit according to the 
manufacturer’s instructions (Ambion, Austin, TX, USA). The RNA was treated 
with DNase 1 to remove DNA contamination. Reverse transcription and PCR were 
performed using Ambion’s RETROscript® kit. The human PCR primers 
(forward/reverse [5’–3’]) are listed in Table 4.1. Human glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) and dH2O were used as positive and negative 
controls, respectively. 
Table 4.1 List of primers of AVP receptor genes for RT-PCR 
 
Gene Forward primer  
(5’-3’) 
Reverse primer  
(5’-3’) 
Size 
(bp) 
C/EBPα CGGTGGACAAGAAC
AGCAAC 
CGGAATCTCCTAGTCC
TGGC 
365 
C/EBPβ 
 
CACAGCGACGACTG
CAAGATCC  
CTTGAACAAGTTCCGC
AGGGTG 
188 
PPARγ2 GCTGTTATGGGTGAA
ACTCTG 
ATAAGGTGGAGATGC
AGGTTC 
325 
 
aP2  TGGTTGATTTTCCAT
CCCAT  
TACTGGGCCAGGAATT
TGAT 
150 
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(Table 4.1 continued) 
 
4.2.4 Quantitative RT-PCR 
From each sample, 2μg of total RNA was reverse-transcribed into 20μl of 
cDNA. Each PCR was prepared by mixing 2μl of the cDNA with 2x SYBR Green 
PCR master mix (Bio-Rad, Hercules, CA, USA) and gene-specific primers (Table 
4.2). The PCR was carried out with ABI 7300 real-time PCR system (Life 
Technologies, Grand Island, NY, USA) to obtain the CT value. Relative gene 
expression (RGE) was calculated by the delta CT method using β-actin as the 
endogenous control for normalization and cyclophilin B as the reference control 
with an RGE of 1.  
Table 4.2 List of primers of adipogenic marker genes for quantitative RT-PCR  
 
 
 
 
Gene Forward primer 
(5’-3’) 
Reverse primer 
(5’-3’) 
Size 
(bp) 
Adiponectin GGCCGTGATGGCAG
AGAT 
TTTCACCGATGTCTCC
CTTAGG 
88 
LPL GAGATTTCTCTGTAT
GGCACC 
CTGCAAATGAGACACT
TTCTC 
276 
Leptin GGCTTTGGCCCTATC
TTTTC 
GCTCTTAGAGAAGGCC
AGCA 
325 
Cyclophilin B GGAGATGGCACAGG
AGGAAA 
CGTAGTGCTTCAGTTT
GAAGTTCTCA 
72 
Gene Forward primer  
(5’-3’) 
Reverse primer  
(5’-3’) 
Size 
(bp) 
AVP V1a 
receptor 
CAGGTGTTCGGCATG
TTTG 
ACCAGATGTTGTAGCA
GATGAA 
343 
AVP V1b 
receptor 
CTCATCTGCCATGAG
ATCTGTAA 
CCACATCTGGACACTG
AAGAA 
249 
AVP V2 
receptor 
ATTCATGCCAGTCTG
GTGC 
TCACGATGAAGTGTCC
TTGG 
422 
GAPDH AACAGCGACACCCA
CTCCTC 
GGAGGGGAGATTCAG
TGTGGT 
258 
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4.2.5 Calcium imaging analysis 
 
 Cells were loaded with 2μM Fura-2AM for 30 min at 37°C. The imaging 
buffer containing (in mM): NaCl 136, KCl 4.8, CaCl2 1.2, MgSO4 1.2, HEPES 10, 
glucose 4, and 0.1% BSA, pH 7.3 was used for Fura-2AM loading and perfusion 
throughout the experiments. Calcium measurements were obtained using a dual 
excitation fluorometric imaging system (TILL-Photonics, Gräfefingen, Germany) 
controlled by TILLvisION software. Fura-2AM loaded cells in perfusion chamber 
were excited by 340nm and 380nm wavelengths. Fluorescence emissions were 
sampled at a frequency of 1 Hz and computed into relative ratio units of the 
fluorescence intensity of the difference of wavelengths (F340/F380). Data were 
expressed as averages from several cells from three separate experiments.  
4.2.6 Induction and detection of lipid droplets 
Cells reaching between 80% and 90% were induced with differentiation 
medium containing DMEM/Ham’s F-12 supplemented with 3% FBS, 0.25mM 3-
isobutyl-1-methylxanthine (IBMX), 33µM biotin, 17µM d-calcium panthothenate, 
100nM human insulin, 1µM dexamethasone and 5µM rosiglitazone for 3 days. 
Adipocyte medium having the same composition as differentiation medium except 
for IBMX and rosiglitazone was changed every 3 days from day 3 to day 21 [39]. 
To test the effect of AVP on adipogenesis, 100nM AVP was supplemented to the 
adipogenic medium and changed every 2 days until day 14 of differentiation. 
Adipogenesis was determined by Oil Red O (ORO) staining. Briefly, cells were 
washed with PBS, fixed with 10% formalin for 10 min, washed twice with dH2O, 
and incubated with 60% isopropanol for 5 min. Cells were then stained with ORO 
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solution for 5 min and washed again to remove excess dye. The presence of lipid 
droplets was visualized by phase contrast microscopy using an inverted microscope 
(Zeiss, Thornwood, NY, USA). 
4.2.7 Data analysis 
Adipocyte count was performed from a total of 36 or 18 frames taken at 10x 
magnification from each group using software ImageJ (1.47v; 
http://imagej.nih.gov/ij). The peak Ca2+ signals and adipocyte counts are shown as 
means ± S.E.M. and were analyzed using a two-tailed and unpaired Student’s t-test 
(GraphPad Software Inc., La Jolla, CA, USA). Statistical significance was 
established at P<0.05. 
4.3 RESULTS 
4.3.1 hASCs differentiate into adipocytes and express the V1a receptor gene  
In order to demonstrate that hASCs can differentiate into adipocytes, we 
cultured the cells in adipogenic media and examined the differentiated cells with 
ORO staining at the end of 14 days. Adipogenesis was confirmed by the presence 
of lipid droplet accumulation (Figure 4.1,A). Next, we examined the type of AVP 
receptor in hASCs at day 0 and 14 of differentiation. RT-PCR analysis revealed 
V1a receptor gene expression, but not V1b or V2 (Figure 4.1,B). 
4.3.2 AVP increases intracellular Ca2+ in hASCs under growth and adipogenic 
conditions  
 
Since hASCs expressed the V1a receptor before and after differentiation, 
we performed real-time Ca2+ imaging analysis to investigate the responses to AVP. 
Stimulation of cells with 1µM AVP increased intracellular Ca2+ at days 0, 7, 14 and 
21 of differentiation (Figure 4.2,A). However, there was a greater response to AVP  
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Figure 4.1 hASCs differentiation into adipocytes and expression of the V1a 
receptor gene. (A) hASCs were differentiated into adipocytes for 14 days and 
stained with Oil Red O (ORO) for the presence of lipid droplets (20x 
magnification). (B) hASCs expressed the V1a receptor gene at day 0 and day 14 of 
differentiation. RT-PCR was performed with specific human V1a, V1b, V2 
primers. dH2O and GAPDH served as negative and positive controls, respectively. 
 
at day 14 compared to  day 21 of differentiation (Figure  4.2,B). Therefore, we 
chose day 14 for our experiments since at this time period, we also detected 
adipocyte differentiation. To confirm the AVP responses in hASCs, cells were 
stimulated with 0.003-1µM AVP that resulted in a concentration-dependent 
increase in [Ca2+]i with a peak at 1µM concentration (Figure 4.2,C and D). In order 
to test whether the V1a receptor indeed mediated the effect of AVP, cells were 
pretreated with 0.0001-1µM V2255, a selective V1a receptor antagonist. V2255 
inhibited the Ca2+ signals in a concentration-dependent manner in both 
undifferentiated and differentiated cells (Figure 4.3,A-D).  
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Figure 4.2 hASCs are responsive to AVP prior to and during adipogenesis. (A) 
Average Ca2+ signals in response to AVP from day 0 to day 21 of differentiation. 
(B) The AVP response increased until day 14, but decreased at day 21. (C) Average 
Ca2+ signals in response to increasing AVP concentration. (D) Average peak 
responses to different AVP concentrations. Values are means ± S.E.M.; n = 86-705 
cells; * P<0.0001 compared to day 0. 
 
 
 
Figure 4.3 The V1a receptor mediates AVP signaling in hASCs. (A, B) Average 
traces and peak Ca2+ signals generated by AVP after V2255, a selective V1a blocker 
pretreatment at day 0. (C, D) Same experiments as in A and B, except at day 14 of 
adipogenic differentiation. Values are means ± S.E.M.; n = 51-433 
cells/concentration. 
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4.3.3 AVP increases intracellular Ca2+ via the PLC-IP3 pathway 
AVP stimulates Ca2+ signals via the V1a receptor in smooth muscle and 
intestinal epithelial cells by activating the phospholipase C enzyme (PLC) [40, 
41].Therefore, we utilized the PLC blocker, U73122 to test whether it could inhibit 
AVP signaling. U73122 (2-12µM) pretreatment for 5 min inhibited the responses 
to AVP in a concentration-dependent manner (Figure 4.4,A and B). Pretreatment 
of cells with U73343, an inactive analog of U73122 did not alter the responses to 
AVP (Figure 4.4,C and D). Since IP3 is a downstream second messenger to PLC,  
 
Figure 4.4 Involvement of PLC in the AVP mechanism in hASCs. (A, B) Averages 
and peak Ca2+ signals generated by AVP after pretreatment of cells with the PLC 
inhibitor, U73122. (C, D) Averages and peak Ca2+ signals after pretreatment with 
U73343, an inactive analog of U73122. Values are means ± S.E.M.; n = 59-81 
cells/concentration; * P<0.0001. 
 
we utilized 2-APB, an IP3 receptor blocker. Pretreatment of cells for 5 min with 10-
300µM 2-APB inhibited the responses to AVP in a concentration-dependent 
manner (Figure 4.5,A and B). In addition, we compared the maximum AVP 
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response in hASCs to those of 2µM ionomycin and 100µM ATP, another Gq-
coupled receptor agonist (Figure 4.5,C and D). 
 
Figure 4.5 IP3 binding to its receptor initiates the Ca
2+ signals. (A, B) Average Ca2+ 
signals and peak responses after pretreatment of cells with 2-ABP, a selective IP3 
receptor blocker. Values are means ± S.E.M.; n = 77-705 cells/concentration. (C, 
D) Average Ca2+ signals and peak responses induced by ionomycin, AVP and ATP 
in hASCs. Values are means ± S.E.M.; n = 102-131 cells/concentration. 
 
4.3.4 Sources of Ca2+ for AVP signals 
In bone marrow-derived stem cells, Ca2+ influx and release from the ER 
generate the Ca2+ signals [42]. Hence, we tested in hASCs the contribution of 
extracellular Ca2+ on AVP signaling by performing experiments under Ca2+ free 
buffer condition. Removal of extracellular Ca2+ significantly reduced the Ca2+ 
signals compared to control cells in Ca2+ containing buffer (Figure 4.6,A). Next, we 
pretreated cells with thapsigargin (TG) for 20 min, a Ca2+-ATPase pump inhibitor 
in the ER to investigate the impact of intracellular Ca2+ on AVP signals. Depletion 
of Ca2+ stores with TG completely abolished the responses to AVP (Figure 4.6,B).  
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Under extracellular free Ca2+ and TG conditions, AVP also failed to increase 
intracellular Ca2+ (Figure 4.6,C and D). 
 
Figure 4.6 Intracellular Ca2+ release and influx are sources for the Ca2+ signals. (A) 
Average Ca2+ signals during AVP stimulation under extracellular Ca2+ and Ca2+ free 
conditions. (B) Depletion of ER Ca2+ stores with thapsigargin (TG) abolished the 
AVP responses. (C) Experiments performed under extracellular Ca2+ free condition 
and TG simultaneously. (D) Average peak responses from experiments in A–C. 
Values are means ± S.E.M; n = 63-705 cells/treatment; * P<0.0001 compared to 
peak control group. 
 
4.3.5 AVP inhibits adipogenesis during hASC differentiation  
To investigate the effect of AVP on adipogenesis, we supplemented the 
differentiation medium with 100nM AVP which enhances differentiation of other 
cell types [24, 43, 44]. AVP supplementation reduced lipid droplet accumulation as 
determined by ORO staining (Figure 4.7,A-C) and decreased adipocyte formation 
compared to control cells without AVP (Figure 4.7,D). The hormone also decreased 
the expression of adipocyte marker genes: CCAAT/enhancer-binding protein α 
(C/EBPα), CCAAT/ enhancer-binding protein β (C/EBPβ), peroxisome 
proliferator-activated receptor γ 2 (PPARγ2), adipocyte protein 2 (aP2),                                      
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adiponectin, lipoprotein lipase (LPL) and leptin compared to control group without 
AVP after 14 days of differentiation (Figure 4.8). 
 
Figure 4.7 AVP inhibits adipogenesis during hASC differentiation. (A, B) Bright-
field and ORO staining images taken at day 14 of differentiation from AVP treated 
and control group without AVP (10x magnification). (C) Adipocyte morphology 
shown at 20x magnification from cells in A and B. (D) Adipocyte count per frame 
from a total of 36 frames from each group. Values are means ± S.E.M; n = 471 
(+AVP) and 1213 (-AVP) cells; * P<0.0001. 
 
 
Figure 4.8 AVP down-regulates adipocyte marker genes in hASCs. Stimulation of 
cells with AVP during 14 days of adipogenic differentiation decreased the 
expression of adipocyte marker genes compared to control cells in the absence of 
AVP. 
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4.3.6 V1a receptor blocker V2255 reverses the effect of AVP on adipogenesis  
Finally, to confirm the effect of AVP on adipocyte differentiation we 
performed adipogenic experiments with the V1a receptor blocker V2255. AVP  
(100nM) supplementation significantly reduced the number of adipocytes as 
indicated by lipid droplet accumulation and ORO staining. When V2255 (100µM) 
was added to the differentiation medium along with AVP, it reversed the inhibitory 
effect of AVP on adipogenesis (Figure 4.9,A and B). In the study, V2255 alone did 
not alter adipocyte formation.  
 
Figure 4.9 V1a receptor blocker reverses the effect of AVP on adipogenesis. (A) 
Bright-field and ORO staining images taken at day 10 of differentiation from 
control adipogenic medium alone and AVP, AVP+V2255 or V2255 supplemented 
groups (10x magnification). (B) Adipocyte count per frame from a total of 18 
frames from each group. Values are means ± S.E.M; n = 1869 (control adipogenic 
medium), 725 (+AVP), 1805 (+AVP and V2255), and 1723 (+V2255) cells; * 
P<0.001. 
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4.4 DISCUSSION                                                                                                   
The role of AVP (a.k.a. anti-diuretic hormone) in water conservation during 
dehydration is well established. It acts by promoting translocation into the plasma 
membrane of tubular cells to allow water reabsorption [45]. Other studies revealed 
that the hormone is capable of stimulating cellular growth and proliferation. Despite  
the identification of AVP receptors in stem cells [44], its function in Ca2+ signaling 
and differentiation remains largely unexplored. We investigated the mechanism of 
AVP signaling and its impact on adipocyte differentiation in hASCs, which is a 
well-accepted stem cell type for adipogenic studies [46]. When placed in 
adipogenic medium, accumulation of lipid droplets can be evidenced within the cell   
population that resembles the characteristics of mature adipocytes. We 
demonstrated that undifferentiated hASCs and differentiated adipocytes express the 
V1a receptor, but not the V1b or V2. This observation differs from mouse 
embryonic stem cells that express all three receptor subtypes [44]. It is possible that  
the pluripotent nature of embryonic stem cells compared to multipotent adult stem 
cells may be accountable for this variation. The possibility of AVP receptor 
variation among species also needs to be considered. Since V1a receptors are 
coupled to Gq-proteins that utilize the PLC-IP3 pathway and Ca2+ signaling [47-
49], we examined whether the Ca2+ signals observed in hASCs during AVP 
stimulation was a result of this mechanism. In addition, we investigated the impact 
of the hormone on adipocyte differentiation. 
Initial experiments demonstrated that hASCs are responsive to AVP 
throughout the differentiation process, with a peak Ca2+ increase at day 14, but 
117 
 
decreases at day 21. Other types of adult stem cells (e.g. bone marrow derived) 
exhibit similar Ca2+ signaling pattern during the terminal stages of osteoblast and 
adipocyte differentiation [17, 18]. It is reasoned that these signals are important for 
directing and terminating the differentiation process.  Furthermore, we confirmed 
the V1a receptor as the type mediating the effect of AVP before and after 
differentiation. The V1a receptor blocker V2255 inhibited the responses to AVP in 
a concentration-dependent manner, which is consistent with the RT-PCR data 
showing V1a gene expression in hASCs. Since receptors coupled to Gq proteins in 
hASCs activate the PLC enzyme [38], we utilized U73122, a PLC inhibitor to test 
whether it mediated the effects of AVP. Indeed, pretreatment of cells with U73122 
inhibited the Ca2+ signals, but not U73343, an inactive analog. Next, we examined 
the effect of IP3 a downstream second messenger to PLC on ER Ca
2+ release. 
Pretreatment of cells with 2-APB, an IP3 receptor blocker inhibited the AVP 
responses in a concentration-dependent manner. These findings revealed that the 
mechanism by which AVP signals in hASCs is by activating V1a receptors and the 
PLC-IP3 pathway. In view that 2-APB abolished the AVP response, it indicated 
that ER Ca2+ release was a source for the Ca2+ signals. To test this hypothesis and 
to determine whether extracellular Ca2+ was involved, we performed experiments 
with TG and under extracellular Ca2+ free conditions. Depletion of Ca2+ stores by 
TG resulted in a complete suppression of the AVP responses, but not in the absence 
of extracellular Ca2+. Under both conditions, AVP also failed to increase 
intracellular Ca2+. From these results, it is clear that both Ca2+ release and influx 
are required for AVP signaling in hASCs. While most of the Ca2+ appears to come 
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from the extracellular space, the ER release is needed to initiate the process. These 
observations are consistent with those reported for Gq-coupled receptor hormones 
that utilize the PLC-IP3 pathway. This mechanism involves both Ca
2+ release  from 
the ER followed by the opening of store-operated Ca2+ channels in the plasma 
membrane via the Ca2+ sensor STIM-1 and Orai1 [50, 51]. One important question 
that needed to be addressed was the effect of AVP on adipogenesis. This was 
determined by supplementing the adipogenic differentiation medium with AVP 
followed by adipocyte quantification and marker gene expression in the cell 
population. The data demonstrated an inhibitory effect of AVP on adipogenesis 
since the number of adipocytes was significantly reduced. In addition, key 
adipogenic marker genes (e.g. C/EBPα, C/EBPβ, PPARγ2) were down-regulated. 
It is possible that AVP’s effect on adipogenesis may involve MAPK/Erk signaling 
since this pathway is activated by the hormone and V1a receptors [52, 53]. This is 
supported by findings in bone marrow-derived stem cells where inhibition of 
MAPK/Erk facilitates adipocyte differentiation [54, 55]. Furthermore, MAPK/Erk 
signaling phosphorylates PPARγ leading to decreased transcriptional activity and 
suppression of adipogenesis [56]. Most importantly, Ca2+ signals inhibit 
adipogenesis by down-regulating C/EBPα, C/EBPβ, C/EBPγ and PPARγ genes in 
preadipocytes via MAPK/Erk [57].  
Based on our results and those presented by others, it appears that AVP 
exerts mainly an inhibitory effect on adipocyte metabolism and differentiation. This 
is based on the fact that the absence of V1a receptor in knockout mice enhances 
lipolysis but decreases glucose uptake by adipocytes [28, 58]. AVP also inhibits β-
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oxidation of fatty acid as an alternative energy source for the body [30]. The 
inhibitory effect of AVP on adipocyte differentiation could be reversed by the V1a 
receptor blocker V2255 which confirms its role on adipogenesis. It is tempting to 
speculate that the reduction in plasma AVP levels during obesity or multiple 
symmetric lipomatosis might be one of the factors responsible for adipose tissue 
accumulation/formation. Additional studies in V1a receptor knockout mice and 
humans with V1a receptor mutation show a tendency to develop obesity and 
diabetes [59, 60]. A link between AVP and body weight gain in cigarette smokers 
after quitting has been established due to the stimulatory action of nicotine on AVP 
secretion [37]. These observations together with our findings in hASCs could 
provide insights into new therapies for obesity. 
In conclusion, we have identified the V1a receptor as the only type for AVP 
in hASCs. This receptor mediates the effect of AVP on intracellular Ca2+ signaling 
by activating Gq-proteins and the PLC-IP3 pathway. This mechanism appears to 
exert an inhibitory effect on adipogenesis by down-regulating the expression of key 
adipogenic genes. 
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CHAPTER 5: CONCLUDING REMARKS 
5.1 SUMMARY OF FINDINGS AND SIGNIFICANCE OF THE RESEARCH 
 
Calcium signaling plays an important role in many cell functions such as 
differentiation, proliferation, apoptosis, and muscle contraction [1]. Chapter 1 of 
this dissertation summarizes the different types of stem cells, the Ca2+ signaling 
mechanisms, the TRPM4 channel and AVP’s impact on Ca2+ signals. We utilized 
rDFSCs and hASCs to investigate the role of TRPM4 and AVP on stem cell 
differentiation. Chapter 2 describes our findings on the role of TRPM4 in rDFSCs. 
We generated TRPM4 knockdown cells to investigate its effect on osteogenesis and 
adipogenesis. After 14 days in differentiation media, TRPM4 knockdown showed 
enhanced mineralization and decreased lipid droplet accumulation. Microarray 
analysis revealed upregulation of critical genes for bone formation such as LUM 
and MEPE, and downregulation of ASPN, which inhibits differentiation and 
mineralization [2]. Several adipogenic genes, for example, TRIB3 and SFRP1, 
decreased in expression; TRIB3 is crucial for adipocyte formation and SFRP1 
enhances adipogenesis in human and mice [3, 4]. The Ca2+ signals generated by 
ATP changed from a biphasic pattern to a gradual and sustained increase with 
TRPM4 inhibition. Therefore, we identified for the first time TRPM4 in stem cells 
and demonstrated that it is a key regulator of Ca2+ signals that facilitates 
adipogenesis but inhibits osteogenesis in rDFSCs.  
As hASCs are a more suitable model for adipogenic studies, we investigated 
the role of TRPM4 in these cells in Chapter 3. We identified TRPM4 gene 
expression in hASCs and human adipose tissue. We also characterized the channel 
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in these cells. Our findings from the adipogenic studies were similar to those in 
rDFSCs since TRPM4 knockdown inhibited adipocyte formation and decreased 
adipocyte marker genes (PPARγ2, C/EBPα, C/EBPβ, aP2 and adiponectin). 
However, the Ca2+ signals with TRPM4 knockdown were different from rDFSCs 
and resembles those observed in pancreatic α and β cells which are excitable cells. 
We found that hASC gene expressed the L-type VDCCs (Cav1.2) which contributed 
to Ca2+ signals stimulated by histamine. This is important since undifferentiated 
stem cells are considered as non-excitable cells with SOCs as their main Ca2+ entry 
pathway [5]. The difference in the Ca2+ pattern between rDFSCs and hASCs may 
be due to the type of MSCs, species or impact of other pathways during 
differentiation.  
In Chapter 4, we investigated the effect of AVP on adipogenesis of hASCs. 
We showed for the first time V1a receptor gene expression in hASCs. AVP in this 
stem cell type inhibited adipogenesis. This is in accordance to V1a receptor 
mutation or knockout that leads to obesity and diabetes [6, 7]. Our result provides 
insight into the mechanism of AVP on adipogenesis. 
The decrease in intracellular Ca2+ during histamine stimulation in hASCs 
after TRPM4 suppression inhibited adipogenesis and was similar to our findings 
with AVP supplementation to the adipogenic medium. Therefore, it is likely that 
other signaling pathways may contribute to this process. In fact, Ca2+ signaling can 
crosstalk with other pathways such as cAMP because Ca2+ release from the ER 
activates STIM1 and increases cAMP signaling [8]. Activation of the V1a receptor 
by AVP also stimulates phosphatidylcholine hydrolysis by phospholipase A2. This 
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results in arachidonic acid production, increased phospholipase D and Na+/H+ 
exchanger activity. These effects control gene expression and protein synthesis 
during  the differentiation process [9].  
5.2 FUTURE STUDIES 
TRPM4 facilitates adipogenesis, but inhibits osteogenesis in rDFSCs. To 
confirm these observations, we will rescue TRPM4 expression and perform a 
differentiation experiment to determine if the effect can be reversed in TRPM4 
knockdown cells. To do that, we will design TRPM4 siRNA against the 3′-
untranslated regions (UTR) of the endogenous TRPM4 gene. Then, we will 
transfect a vector containing the coding sequence for TRPM4 without the 3'-UTR. 
Therefore, TRPM4 overexpression from the vector construct will not be affected 
by the siRNA whereas the endogenous TRPM4 mRNA will be degraded. We will 
confirm TRPM4 expression by RT-PCR and Western blot. Functional studies will 
be performed with patch-clamp, ARS and ORO staining, Ca2+ imaging analysis, 
and quantitative RT-PCR. By patch-clamp, we will compare the amplitude of 
TRPM4 currents to those of control cells. ARS and ORO staining, Ca2+ imaging 
analysis, and quantitative RT-PCR will be performed during differentiation at days 
0, 7, 14, 21 to determine whether the effect of TRPM4 knockdown can be reversed.  
Furthermore, we will investigate the effect of TRPM4 in vivo. We plan to 
examine the ability of TRPM4 knockdown rDFSCs in bone repair of critical-size 
calvarial defects in the rat model. We will use micro-CT imaging, perform 
histologic analysis, and confirm osteogenic marker gene expression for new bone 
formation [10]. Regarding a pharmacological approach, 9-phenanthrol, a TRPM4 
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selective blocker can be toxic to the cells; therefore, it has limited potential in 
clinical therapy [11]. Other TRPM4 blockers such as flufenamic acid, an anti-
inflammatory drug, and glibenclamide, the antidiabetic drug; both have been 
approved by the FDA [11, 12]. However, they also interact with other ion channels 
which can cause many side effects. As a consequence, more research needs to be 
done to identify specific TRPM4 blockers to control obesity and osteoporosis in the 
future.  In conclusion, our results provided insights into the molecular mechanisms 
controlling stem cell differentiation by the TRPM4 ion channel and the hormone 
AVP. These findings could potentially lead to new therapies for the treatment of 
obesity and bone defects. 
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